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ABSTRACT
Colorectal cancer (CRC) is the third most frequent cancer and the second leading
cause of cancer related deaths. While CRC is initiated by mutations in critical tumor
suppressor genes, its development and progression to malignancy is aided by host derived
cells that are recruited to the tumor microenvironment (TME) and by cancer-associated
microbiota that constitute the gut microbiome. Components of the gut microbiota have
been shown to alter immune cell infiltration into tumors and influence response to
therapy, disease stage, and patient survival. In previous studies, we found that ApcMin/+
mice, a model of early colon carcinogenesis, had reduced tumor burden when weaned to
a folate free (FF) diet as compared to mice weaned to regular rodent chow (RC). When
subjected to systemic therapy with 5-FU, tumor response in mice on the folate free diet
was more cytotoxic as compared to mice on rodent chow, where tumor response was only
cytostatic, with tumor burden rebounding to untreated levels upon removal of 5-FU.
The goal of this study was to identify alterations in the gut microbiome
composition in ApcMin/+mice on the different diets, RC, FF, and FF+FA. The FF and
FF+FA diets are both defined diets that contain the antibiotic succinyl sulfathiazole
(SST), which prevents the production and absorption of folate. The distinguishing factor
amongst these diets was that the FF diet contains no folic acid (FA) and the FF+FA diet
contains 6 parts per million (ppm) FA. The FF+FA diet contains similar levels of FA that
are present in the crude RC diet, which is a standard diet for mice.
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The results showed significant changes in the gut microbiome composition
between RC, FF, and FF+FA diets with additional changes upon treatment with 5-FU.
The Bacteroidetes S24-7 population was nearly eliminated in mice fed the FF and FF+FA
diets, while the Firmicutes Ruminococcus and Clostridiales populations expanded. In
addition, the concentration and production of metabolites, specifically short chain fatty
acids (SCFAs), were significantly reduced when mice were fed the FF and FF+FA diets,
and these levels remained at low levels during treatment with 5-FU. This correlated with
reduced infiltration of immune cells into the TME. Mast cells, macrophages, myeloid
derived suppressor cells (MDSCs), T-regulatory cells, and CD8 cytotoxic T cells were
significantly reduced in the TME when mice were fed the FF and FF+FA diets, and these
levels remained low during treatment with 5-FU. Although similar results were observed
in mice fed the FF and FF+FA diets, tumor burden was reduced by 70% when mice fed
the FF diet were treated with 5-FU as compared to untreated controls. Mice fed the
FF+FA diet that were treated with 5-FU only had a mild 30% reduction in tumor burden
as compared to untreated controls. These data suggest that elimination of folate from
dietary intake and the gut microbiota was essential to enhance the cytotoxicity of 5-FU.
However, because the FF and FF+FA diets are both defined diets and contain the
antibiotic, SST, it was important to distinguish the effects of the removing dietary folate
versus inhibiting gut microbe folate production. Mice were fed a basal and FF diet that
were defined diets lacking SST, designated as basal and FF* diets, respectively, and then
subjected to 5-FU therapy. The basal diet contained 6 ppm FA whereas the FF* diet
contained no FA and no SST. The results showed that removal of SST reversed the
previous effects on the gut microbiota, ie, the Bacteroidetes S24-7 population was
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restored and the Firmicutes Ruminococcus and Clostridiales populations returned to
lower levels in mice fed the basal and FF* diets that was similar in abundance to that in
mice fed the RC diet. However, the composition of SCFAs remained significantly lower
in mice fed the basal and FF* diets, and remained low during treatment with 5-FU. The
infiltration of mast cells, macrophages, MDSCs, and T-regulatory cells were significantly
lower in the TME as compared to mice fed the FF and FF+FA diets containing SST.
While tumor burden was 15% lower in mice fed the basal and FF* diets, treatment with
5-FU caused a modest 30% reduction in tumor burden as as compared to untreated
controls and similar to that observed in mice fed RC diet. These results highlight the
importance of inhibiting folate production by the gut microbiota in influencing the
activation and infiltration of immune cells into the TME, and enhancing the cytotoxic
effects of 5-FU.
These studies show that understanding the role of the gut microbiome in response
to 5-FU could lead to the development therapeutic strategies targeting the gut
microbiome to alter its metabolites in order to enhance the antitumor efficacy of 5-FU
while minimizing its cytotoxic effects to the patient.
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CHAPTER 1
INTRODUCTION
1.1 COLORECTAL CANCER
Colorectal cancer (CRC) is the third most frequent cancer and the third leading cause
of cancer related deaths in the United States ("Cancer Facts and Figures"; Jin et al.). In
2018, the American Cancer Society estimated that 140,250 new cases of CRC will be
diagnosed and 50,630 deaths would occur ("American Cancer Society"; Jin et al.).
Globally, the estimated incidence of CRC in 2012 was 1,360,000, and the estimated
mortality was 694,000. Increased awareness and screening has reduced the mortality
from the disease as CRC is being detected and treated at earlier stages (Pompei et al.;
"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in
2012") when the survival rate is high. Early screening for CRC has proven to be highly
effective as the incidence of CRC deaths has decreased by half since 1975 ("Cancer Facts
and Figures"). Although polyps are starting to be detected and treated before they become
malignant and invasive, the incidence of CRC has remained high and continues to
increase, particularly in individuals under 50 years of age.
Unfortunately, most of the steps leading to CRC progression are asymptomatic
making its detection at an early stage, when intervention may prevent its progression,
very difficult and problematic ("Cancer Facts and Figures"). By the time that CRC is
diagnosed, only 40% of patients present with tumors at the early primary stages
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suggesting that the majority of CRC is detected when the cancer has already metastasized
("Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in
2012"; "Survival Rates for Colorectal Cancer, by Stage"). When CRC is detected at early
stages, the five-year survival rate is greater than 90% ("Globocan 2012: Estimated Cancer
Incidence, Mortality and Prevalence Worldwide in 2012"; "Survival Rates for Colorectal
Cancer, by Stage"). However, when CRC has spread to lymph nodes and distant organs,
the five-year survival rate drops dramatically to less than 12% (Figure 1.1) ("Cancer
Facts and Figures"; "Survival Rates for Colorectal Cancer, by Stage"). Therefore,
understanding the biological processes that drive tumor development and progression are
crucial for the development of novel strategies for early detection and therapies to
improve disease control and patient outcome.
CRC is most frequently the result of sporadic, non-inheritable mutations in the
adenomatous polyposis coli (APC) gene, and less than 5% of patients diagnosed with
CRC will inherit a mutation in the APC gene in germ cells (A R Moser et al.; A. R.
Moser et al.; Daniel et al.). Sporadic cancers begin with a mutation in the APC gene
resulting in the formation of polyps and genomic instability (Daniel et al.; Fearon and
Vogelstein). Subsequent mutations occur that turn off tumor-suppressor genes and turn
on proto-oncogenes transforming the polyp into a malignant tumor (Daniel et al.; Fearon
and Vogelstein). Additional mutations further modulate the tumor and its
microenvironment enabling the its invasion through the basement membrane and
metastasis to distant organs, most frequently, the liver and the lungs (Daniel et al.; Fearon
and Vogelstein).
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1.2 INHIBITORS OF THYMIDYLATE SYNTHASE: 5-FLUOROURACIL
Thymidylate Synthase (TYMS) is an S-phase enzyme that catalyzes the reductive
methylation of deoxyuridine monophosphate (dUMP) by methylene tetrahydrofolate
(CH2H4PteGlu) to form deoxythymidine monophosphate (dTMP) (Figure 1.2B)
(Longley, Harkin and Johnston; Information "2-Fluoropyrimidine"; Information
"Fluorouracil"; Valeriote and Santelli) Uracil is one of the four nucleotides that are
incorporated into RNA. Methylation of uracil at the C-5 position produces thymine which
is one of the four nucleotides that become incorporated into DNA during synthesis.
TYMS is the enzyme that catalyzes this conversion and this enzymatic reaction is the sole
source of dTMP for DNA synthesis in rapidly proliferating cells thus, TYMS is a critical
target for anti-cancer agents (Information "Fluorouracil"; Information "2Fluoropyrimidine"; Longley, Harkin and Johnston).
5-Fluorouracil (5-FU) is an analogue of uracil that contains a fluorine atom at the C-5
position instead of a hydrogen atom (Figure 1.2A) (Information "2-Fluoropyrimidine").
5-FU is an antimetabolite that functions dually by (1) inhibiting the S-phase enzyme
TYMS and (2) misincorporating fluoropyrimidines into DNA and RNA (Jin et al.;
Longley, Harkin and Johnston; Information "Fluorouracil").
Mechanistically, the substrate fluoro-deoxyuridine monophosphate (FdUMP) binds to
the nucleotide binding site of TYMS and forms a stable ternary complex with the enzyme
and the cofactor methylene tetrahydrofolate (CH2H4PteGlu), and thereby blocking the
binding of the normal substrate, dUMP (Longley, Harkin and Johnston) and resulting in a
dead enzyme. 5-FU can also be mis-incorporated into DNA and RNA which results in
DNA or RNA fragmentation. TYMS inhibition results in depletion of dTMP leading to
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an imbalance of the deoxynucleotide pool. A disruption specifically in the ratio of
deoxyadenosine triphosphate (dATP) and deoxythymidine triphosphate (dTTP) is thought
to interfere with DNA synthesis and repair and therefore causes severe DNA damage
(Longley, Harkin and Johnston). Studies have shown that 5-FU also disrupts the
processing of pre-rRNA into mature rRNA, post-transcriptional modifications of tRNA,
the assembly and activity of snRNA, and splicing of pre-mRNA (Longley, Harkin and
Johnston; Information "Fluorouracil"). All of these result in apoptosis and cell death.
Despite the importance of this pathway for cell growth, 5-FU is only mildly effective
with only 10% of patients exhibiting a positive response (Longley, Harkin and Johnston;
Johnston and Kaye). However, when 5-FU is combined with other therapies, the efficacy
is enhanced in up to 40% of patients (Longley, Harkin and Johnston; Giacchetti et al.).
For example, Leucovorin (LV), or folinic acid, expands the concentrations of CH2THF,
which stabilizes the binding of TS and FdUMP (Wright et al.; Yasuhiko et al.). Wright et
al. showed that treatment of Balb/c mice that had a subcutaneous injection of the murine
mammary carcinoma cell line, EMT6, with a combination therapy of 5-FU + LV showed
a significant delay in tumor growth as compared to mice treated with 5-FU alone (Wright
et al.). Mice administered with 5-FU had larger tumors as compared to mice treated with
5-FU + LV (Wright et al.), while treatment with LV alone had no significant impact on
tumor growth (Wright et al.). In support of this findings, Nadal et al. used murine colon
cancer cells lines, CT26 (Balb/c) and MC38 (C57Bl/6), to show that pretreatment with
LV before and during treatment with 5-FU significantly delayed the growth and
development of subcutaneous tumors (Nadal). In balb/c mice implanted with CT26 cells,
treatment with 5-FU + LV significantly delayed tumor growth by approximately three-
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fold as compared to treatment with 5-FU alone (Nadal). In C57Bl/6 mice implanted with
MC38 cells, treatment with 5-FU + LV also significantly delayed tumor growth as
compared to treatment with 5-FU alone (Nadal). Similar results were also observed in
vitro when LV was combined with 5-FU treatment (Nadal). Consistent with these results,
Park et al. showed that treatment with 5-FU + LV resulted in 50% growth inhibition in
four human colorectal cancer cell lines, while treatment with 5-FU alone resulted in a
50% growth inhibition in three cell lines (Park et al.). Irinotecan is another anti-cancer
compound that when activated by hydrolysis to SN-38, inhibits the function of
topoisomerase I, which plays a variety of roles during DNA replication and cell division
(Douillard et al.). Douillard et al. showed that the response rate increased by 18% in
patients receiving irinotecan combined with 5-FU as compared patients not receiving
irinotecan alone (Douillard et al.). The time to recurrence, duration of response, and
survival were prolonged in patients receiving irinotecan recipient as compared to those
who did not receive the drug (Douillard et al.). Another common treatment, methotrexate
(MTX), is an antimetabolite drug. MTX is an antifolate that inhibits dihydrofolate
reductase, an enzyme that participates in tetrahydrofolate synthesis by regenerating
methylene tetrahydrofolate, the co-factor (Cronstein). Because tetrahydrofolate is
required for thymine biosynthesis, methotrexate interferes with DNA replication and the
cell cycle (Cronstein). In patients with advanced colorectal cancer, tumor response is
nearly doubled when 5-FU was supplemented with MTX ("Meta-Analysis of
Randomized Trials Testing the Biochemical Modulation of Fluorouracil by Methotrexate
in Metastatic Colorectal Cancer. Advanced Colorectal Cancer Meta-Analysis Project").
This data positively correlated with an increase in overall survival ("Meta-Analysis of
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Randomized Trials Testing the Biochemical Modulation of Fluorouracil by Methotrexate
in Metastatic Colorectal Cancer. Advanced Colorectal Cancer Meta-Analysis Project").
Lastly, interferons (IFNs) are considered potent inhibitors of tumor cell growth. IFN-α
activates natural killer (NK) cells and macrophages that target and destroy tumor cells.
IFN-α is also thought to work with 5-FU to prevent tumor growth (Villar-Grimalt et al.).
Villar-Grimalt et al. showed that patients treated with IFN-β, an IFN with greater antiproliferative activity, and 5-FU showed a 28.8% increase in tumor response (VillarGrimalt et al.). The improved response positively correlated with slower tumor
progression, increased survival, and no significant impact on toxicity (Villar-Grimalt et
al.).
The use of 5-FU in the clinic has been severely limited by toxicity to rapidly dividing
normal cells and acquired resistance (Malet-Martino and Martino). Resistance to 5-FU
has been shown to occur through various mechanisms such as increased TYMS protein
levels, TYMS gene amplification, and/or decreased inhibition of TYMS activity (Jin et
al.). An increase in TYMS activity undermines the activity of 5-FU, which functions to
block this enzymatic pathway. When a tumor acquires mechanisms to overcome the
inhibition by 5-FU, the drug loses its efficacy and the tumor begins to rapidly grow and
divide. This ultimately leads to metastasis and poor patient prognosis. Therefore, it is
essential to discover novel therapeutic strategies to increase the efficacy of 5-FU while
avoiding toxicity and acquired resistance. Targeting other molecules in this pathway may
promote tumor rejection and prevent chemo-resistance. For example, targeting the gut
microbiota during 5-FU treatment may further influence the activity of TYMS and serve
as a powerful tool to suppress its enzymatic activity.
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1.3 FOLATE
Folate is a water soluble vitamin frequently referred to as vitamin B9 (Clinic). A
synthetic version of folate, folic acid (FA) is a very stable compound that is quickly
absorbed by the body; however FA is not well utilized by the body. Folate is a necessary
cofactor in many biological processes including the biosynthesis of amino acids and
nucleotides such as histidine, serine, glycine, methionine, thymidylate, and purine. In
addition, folate is essential in red blood cell formation (Mahmood). A deficiency in folate
can therefore lead to anemia (Bailey and Gregory; Mahmood; Clinic). Folate is most
commonly known for its importance during pregnancy to prevent neural tube defects, or
brain and spine birth defects (Bailey and Gregory; Mahmood; Clinic). Relevant to this
study, during the synthesis of thymidine, FA is converted to methylene tetrahydrofolate
(CH2H4PteGlu) where it functions as a co-factor of TYMS (Longley, Harkin and
Johnston). Therefore, FA metabolism plays a crucial role in TYMS function and DNA
synthesis.
Folate is a vitamin that is not produced by the body, but is obtained through dietary
intake of folate rich foods or vitamin supplements. Folate is rich in dark leafy green
vegetables, beans, nuts, and fruits such as oranges, bananas, and strawberries (Mahmood;
Clinic). In addition, folate is produced by microbes in the gut. Bacteroidetes,
Fusobacteria, and Proteobacteria are considered as the common producers of folate
whereas Actinobacteria and Firmicutes are considered the rare folate producers
(Magnúsdóttir et al.; Rossi, Amaretti and Raimondi). Strains of Bifidobacterium, a
probiotic genera, are also capable of producing folate (Rossi, Amaretti and Raimondi).
Rats fed a probiotic formula containing folate producing bacteria have increased levels of
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plasma folate. In addition, humans fed the same probiotic formula showed increased
levels of folate in their feces suggesting that the gut microbiota may play a critical role in
folate synthesis and circulating levels (Pompei et al.).
1.4 GUT MICROBIOTA
The gut microbiota is comprised of trillions of microorganisms inhabiting the small
intestine, colon, and rectum. The human gut contains approximately 1000 known
bacterial species with more than 3 million genes (Guinane and Cotter). Further increasing
its complexity, each individual’s gut microbiota is unique with only approximately 30%
similarity amongst other individuals. The gut microbiota is like a fingerprint, where no
two individuals have exactly the same composition (Gilbert). It is very unique and
dynamic across individuals which makes learning and understanding its function very
complicated. The gut microbiota varies across individuals within a population due to a
variety of factors. Each individual’s microbiota coevolves with the individual as a result
of age, diet, exercise, geographic location, and exposure to various factors such as
antibiotics, drugs, among others (Brennan and Garrett; Lagier et al.; Levy et al.; Moya
and Ferrer; Schubert, Sinani and D Schloss).
In recent years, the gut microbiome has become an important focus of research. Many
studies over the last decade have shown that the gut microbiome plays an important role
in the healthy development of an individual as well as in the development and
progression of many diseases including but not limited to obesity, diabetes, arthritis,
colitis, and cancer (Brennan and Garrett; Iida et al.; Levy et al.; Malinen et al.; Moya and
Ferrer). Imbalances in the gut microbiota, or dysbiosis, can be detrimental to human
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health. Dysbiosis has been shown to be harmful to the host’s metabolism, physiology,
nutrition, and immune function (Iida et al.; Moya and Ferrer).
Relevant to this study is the fact that genetic mutations modify the gut microbiome
and modulate the development of diseases like colorectal cancer or colitis (Brennan and
Garrett; Couturier-Maillard et al.; Garrett et al.; Levy et al.). For example, CouturierMaillard et al. showed that Nucleotide-binding Oligomerization Domain-containing
protein 2 (NOD2) deficient mice increased the risk of colitis to cohoused wild type (WT)
mice (Couturier-Maillard et al.). NOD2 is a protein that is expressed by numerous cell
populations within the colonic mucosa and maintains microbial tolerance at the intestinal
barrier (Couturier-Maillard et al.). NOD2 deficient mice characteristically have an
expansion of fecal and ileal-associated Bacteroidaceae, which closely mimics the
expansion of Bacteroidaceae observed in humans carrying the NOD2 variant
L1007fsinsC (Couturier-Maillard et al.). In this study, treatment with broad-spectrum
antibiotics reduced the severity of colitis-driven tumorigenesis, as indicated by a
reduction in body weight loss, and decreased the time to progression in both NOD2
deficient and WT mice (Couturier-Maillard et al.). This study suggested that genetic
mutations in critical intestinal barrier and immune regulator genes modified the gut
microbiota which then enhanced inflammation driven diseases like colitis (CouturierMaillard et al.). In support of this notion, Garrett et al. showed that T-bet deficient mice
are more susceptible to colitis when administered dextran sodium sulfate (DSS) (Garrett
et al.). T-bet is a transcription factor that influences the innate and adaptive proinflammatory immune responses (Garrett et al.). T-bet deficient mice displayed a more
severe immune response as indicated by an increase in neutrophils, mononuclear cells,
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and lymphoid aggregates (Garrett et al.). T-bet deficient mice also suffered from
enhanced edema, ulceration, and intestinal crypt loss (Garrett et al.). In addition, cross
fostering recombination activating gene 2 (Rag2) deficient mice, that lack the ability to
generate mature B and T lymphocytes, and WT mice to mothers that were T-bet and
Rag2 double deficient that have severe ulcerative colitis, significantly increased the
colitis histology score of both Rag2-deficient and WT mice as compared to mice that
were nursed by their own mothers (Garrett et al.). This study highlights the capability of
the gut microbiota to initiate colitis by acquiring pathogenic gut microbiota from the
cross fostered mother, despite the genetic resistance to colitis in the WT mice (Garrett et
al.). Finally, Levy et al. used the nucleotide-binding domain, leucine-rich repeatcontaining Protein 6, apoptosis-associated speck-like protein (Nlrp6-Asc) containing a Cterminal caspase recruitment domain (CARD) inflammasome deficiency model to show
that fecal transfer from Nlrp6 deficient mice into WT mice through cohousing promoted
dysbiosis despite the genetic resistance to gut dysbiosis (Levy et al.). Nlrp6 is present
mainly in intestinal epithelial cells and is important for proliferation, mucus secretion,
and mucosal self-renewal (Levy et al.). Mice deficient in Nlrp6 exhibit a distinct gut
microbiota that pre-disposes them to inflammation-induced colorectal cancer among
other intestinal complications (Levy et al.). In addition, Asc is a gene that is
predominantly expressed in intestinal epithelial cells and mice deficient in Asc have gut
dysbiosis that drives inflammation-induced colorectal cancer (Levy et al.). Interestingly,
when germ free (GF) WT mice were cohoused with WT or Asc deficient mice, the GF
mice adopted the gut microbiota composition and diversity of the WT or Asc deficient
mice that they were housed with (Levy et al.). As a result, previously GF WT mice
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housed with Asc deficient mice showed a significant reduction in colonic Interleukin-18
(IL-18) levels, a symptom associated with Asc deficient mice (Levy et al.).
Numerous studies have established that the gut microbiota is distinct in patients with
several different diseases from that of healthy individuals and that bacteria present in the
gut can promote or inhibit disease progression (Baxter et al.; Levy et al.; CouturierMaillard et al.; Elinav et al.; Garrett et al.; Henao-Mejia et al.; Ivanov et al.). In studies
using GF mice, Baxter et al. showed that transplantation of fecal material from three
healthy individuals and three CRC patients revealed six unique microbial profiles (Baxter
et al.). Using an inflammation model of colorectal carcinogenesis, azoxmethane-dextran
sodium sulfate (AOM-DSS), mice received fecal transplant before AOM-DSS exposure
(Baxter et al.). The tumor burden was significantly different among mice receiving
different fecal material and was associated with the microbes present in the gut rather
than the stage of cancer of the fecal donor patient (Baxter et al.). In particular, the
Bacteroidetes B. uniformis, B. fragilis, B. ovatus, B. xylanisolvens, and B.
thetaiotamicron, were the species that were heavily associated with higher tumor burden
(Baxter et al.). On the other hand, the Clostridium group was associated with lower tumor
burden (Baxter et al.). These microbial shifts in the gut were derived from donor mice
after the fecal transplant and prior to receiving the AOM-DSS treatment (Baxter et al.).
However, during treatment with AOM-DSS, the gut microbiome changed the most in the
mice that had the lowest tumor burden, whereas mice with the highest tumor burden
showed the least amount of change in the gut microbiome composition (Baxter et al.).
Conclusions from this study indicated that the mice whose initial community was closer
to the tumor-associated end point community presented with a higher tumor burden
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(Baxter et al.). Consistent with these results, fecal transplantation from mice with
diseases such as non-alcohol fatty liver disease, obesity, colitis, and CRC, into healthy
wild type (WT) mice increased the susceptibility of developing these diseases in the
recipient mice (Levy et al.; Couturier-Maillard et al.; Elinav et al.; Garrett et al.; HenaoMejia et al.; Ivanov et al.).
It is hypothesized that changes in the gut microbiota can promote or enhance
tumorigenesis (Rubinstein et al.; Kostic, Chun, et al.; Kostic, Gevers, et al.; Castellarin et
al.; Zackular, Baxter, Iverson, et al.; Zackular, Baxter, Chen, et al.; Zackular, Rogers, et
al.). For example, colonization of ApcMin/+ mice with Fusobacterium nucleatum (F.
nucleatum) promoted tumor progression and created a pro-inflammatory tumor
microenvironment through the enhanced recruitment of myeloid cells (Rubinstein et al.;
Kostic, Chun, et al.). Specifically, Rubinstien et al. showed that treatment of a variety of
CRC cell lines, HCT116, DLD1, SW480, and HT29, with F. nucleatum increased growth
stimulation by approximately100% (Rubinstein et al.). The mechanism of action
indicated that F. nucleatum contained a virulence factor, FadA, that binds to E-cadherin
on CRC cells (Rubinstein et al.). The interaction between FadA and E-cadherin enhanced
the adherence and invasive properties of F. nucleatum to promote E-cadherin-mediated
colorectal tumor growth (Rubinstein et al.). Consistent with the cell culture model, CRC
patients have been shown to have elevated levels of the FadA gene as compared to
healthy individuals (Rubinstein et al.). In support of these findings, Kostic et al. showed
that CRC patients had an abundance of Fusobacterium spp. in their stool samples at a
level significantly higher than healthy individuals (Kostic, Chun, et al.). In addition,
colonizing ApcMin/+mice with Fusobacterium spp. enhanced the growth and development
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of intestinal tumors, by specifically activating and increasing the infiltration of myeloid
cells (Kostic, Chun, et al.). In particular, myeloid-derived suppressor cells (MDSCs) are
known to play a potent role in suppressing the immune response (Kostic, Chun, et al.).
The results indicated a 3.7-fold increase in MDSCs when ApcMin/+ mice were fed
Fusobacterium spp. as compared to the control group (Kostic, Chun, et al.). In support of
this notion, Castellarin et al. used RNA-sequencing to show that nine out of eleven
patients had at least a 2-fold increase in F. nucleatum in the tumor tissue as compared to
the adjacent healthy tissue (Castellarin et al.).
Aside from F. nucleatum, studies using the AOM-DSS model have shown that
conventionalizing germ-free (GF) mice with the microbiota of tumor-bearing mice
subjected to AOM-DSS increased tumor formation suggesting that negatively altering the
gut microbiota through inflammation contributes to tumorigenesis (Zackular, Baxter,
Iverson, et al.). Targeting the gut microbiota therefore may be a powerful strategy to
prevent inflammation and tumor development. In support of this notion, Zackukar et al.
showed that administering different antibiotic cocktails to specific-pathogen free (SPF)
mice subjected to the AOM-DSS inflammation based model of CRC altered their
susceptibility to tumor development (Zackular, Baxter, Chen, et al.). In this study,
administration of eight different combinations of metronidazole, streptomycin, and
vancomycin into mice resulted in unique gut microbial profiles and subsequently, distinct
differences in tumor burden (Zackular, Baxter, Chen, et al.). These data suggest that
susceptibility to tumorigenesis may be altered by manipulating the microbial community
present in the gut. However, the time at which the gut microbiota is manipulated appears
to be critical.
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Although the gut microbiota plays an essential role in tumorigenesis and progression,
there is also strong evidence suggesting that the gut microbiota can determine the
efficacy and toxicity of chemotherapy (Iida et al.; Yu et al.; Scott et al.; Alexander et al.).
Iida et al. demonstrated the significance of intact commensal microbes in promoting
tumor development (Iida et al.). Using GF mice or conventional mice treated with
antibiotics, they showed that a modulated gut microbiota altered the tumor
microenvironment (TME), specifically the function of myeloid derived suppressor cells
(MDSCs) (Iida et al.). When subjected to oxaliplatin chemotherapy, mice with an altered
microbiota had decreased tumor regression and survival as a result of MDSCs in the
TME suppressing cytokine production, necrosis, reactive oxygen species (ROS), and
cytotoxicity (Iida et al.). In addition, Yu et al. showed that CRC patients with recurrent
tumors following the combined chemotherapy treatment of oxaliplatin and capecitabine
have an abundance of F. nucleatum (Yu et al.). This bacterium was shown to activate
cancer cell autophagy, a survival mechanism used by cancer cells during environmental
stress. The autophagy pathway promoted chemo-resistance through the activation of the
toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MYD88)
pathway (Yu et al.). TLR4 is a pathogen recognition receptor that interacts with the
adaptor molecular MYD88, which facilitates the production of pro-inflammatory
cytokines like IL-6 and Tumor Necrosis Factor- α (TNF-α) (Lei Zhou). This pathway is
involved in tumor invasion and migration, and allows the tumor to avoid immune
surveillance and apoptosis. In addition, the MYD88-TLR4 pathway is known to promote
tumor development and chemo-resistance (X. Chen et al.). In CRC, TLR4 expression is
oncogenic, and TLR4 and MYD88 are elevated in patients with aggressive metastatic
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CRC (Wang et al.; White; Yu et al.). Thus, the gut microbiota is complex and can impact
tumor development, progression, and host survival. Determining the changes in the gut
microbiota during CRC development and treatment is essential to developing therapies to
improve patient prognosis.
1.5 TUMOR IMMUNE MICROENVIRONMENT
Historically it was thought that a tumor was comprised of a homogenous population
of highly proliferative cancerous cells. Thus, therapies were developed to specifically
target rapidly dividing tumor cells. However, patient relapse and tumor recurrence after
therapeutic intervention was frequent (Young et al.). In the last two decades, it has now
been e that tumors are complex tissues composed of a heterogeneous population of tumor
cells that are highly infiltrated with an equally heterogeneous population of nonneoplastic cells that together with the extracellular matrix, where the tumor is embedded,
comprise the tumor microenvironment (TME). The heterogeneous collection of tumorassociated non-neoplastic cells play a critical role in the function and dynamics of the
tumor growth and progression to malignancy (Figure 1.3) (DeClerck et al.; Balkwill,
Capasso and Hagemann; Quail and Joyce).
The cells in the TME include endothelial cells, fibroblasts, innate and adaptive
immune cells that secrete a complex combination of cytokines, chemokines, and growth
factors that have been shown to impact tumor initiation, progression, and response to
therapy (Lagier et al.). In addition, host and tumor interactions have been shown to be
critical for epithelial to mesenchymal transition, tumor invasion and progression to
metastasis (Y. Zhang et al.; DeClerck et al.; Trédan et al.). There is evidence showing
that the tumor cells closely interact with the host immune system during progression to
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malignancy (Y. Zhang et al.). In addition, numerous studies on host-tumor interactions
and signaling have shown that the TME plays a major role in the development and
treatment of cancers (Quail and Joyce; Trédan et al.; Peddareddigari, Wang and DuBois;
Miselis et al.; Lin, Nguyen, et al.; Zeisberger et al.; Lin, Li, et al.; Gounaris et al.; Maltby,
Khazaie and McNagny; Yasuhiko et al.; Kitadai et al.; Crawford et al.; Francia,
Emmenegger and Kerbel; Ryan et al.; O'Callaghan et al.; M.-L. Chen et al.).
For example, Gounaris et al. showed that human CRC tumors and two tumor-bearing
mouse models of CRC had an abundance of mast cells infiltrating the tumor stroma and
submucosa (Gounaris et al.). The mouse models used in this study were the ApcMin/+
mouse and the tamoxifen-inducible Cre recombinase model to produce a mouse strain
that had a stable dominant-acting mutant β-catenin (Gounaris et al.). In addition, TNF-α
was shown to play a potent role in stimulating mast cell colony formation. Treatment of
ApcMin/+ mice with anti-TNF-α antibodies significantly reduced the number of polyps
observed (Gounaris et al.). The polyps present in the mice treated with anti-TNF-α also
had a unique morphology which correlated with a four-fold decrease in the blood vessel
volume and approximately a four-to five-fold decrease in mast cell progenitors (Gounaris
et al.). To confirm the necessity of mast cells for polyp formation, Gounaris et al. lethally
irradiated ApcMin/+ mice and reconstituted their bone marrow (BM) with WT marrow as
well as BM from transgenic mice carrying mutations in genes essential for mast cell
recruitment, Cd34-/- Cd43-/- (Gounaris et al.). Cd34 and Cd43 genes do not impact mast
cell formation; however they are essential for permitting mast cells to traffic into the
peripheral tissues (Gounaris et al.). ApcMin/+ mice reconstituted with Cd34-/- Cd43-/- BM
had a significant mast cell depletion and a significant reduction in the number of polyps
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compared to WT BM recipients (Gounaris et al.). These mice also exhibited decreased
blood vessel densities, decreased mitotic activity, and increased apoptosis of atypical
epithelial cells (Gounaris et al.). Collectively, these data suggest that polyp formation is
highly dependent on mast cells that create a tumor promoting microenvironment. In
support of this notion, Strouch et al. showed that patients with pancreatic cancer had a
significant increase in mast cells infiltration of the tumor stroma compared to healthy
adjacent tissues (Strouch et al.). In addition, elevated mast cell infiltration correlated with
advanced tumor stage (Strouch et al.). Studies in cell culture showed that the primary
pancreatic cancer cell line, PANC1-1, and the metastatic pancreatic cancer cell line,
AsPC1, induced the migration of the mast cell line LAD-2 at higher rates as compared to
a normal human epithelial cell line, HPDE (Strouch et al.). In addition, co-culturing the
PANC-a and AsPC1 pancreatic cell lines with LAD-2 cells significantly increased their
proliferation (Strouch et al.). Taken together, these studies highlighted the necessity of
mast cells in tumor formation, development, and progression. Targeting harmful immune
cells in the tumor stroma such as mast cells may be a valuable strategy to reduce tumor
burden and improve prognosis.
Further studies by Miselis et al. showed that C57Bl/6 mice receiving an
intraperitoneal injection of asbestos-induced mesothelioma cells had an abundance of
macrophages in tumor spheroids and solid tumors (Miselis et al.). Liposome-encapsulated
clodronate (CLIP) is known to prolong the depletion of macrophages and tumor
associated macrophages (Miselis et al.). In this study, Miselis et al. showed that IP
injection of CLIP into tumor-bearing mice caused macrophages to undergo apoptosis
(Miselis et al.). In addition, mice treated with CLIP exhibited smaller residual tumors
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whereas mice treated with PBS had extensive tumor growth and invasion in the
diaphragm (Miselis et al.). Treatment with CLIP resulted in a 17-fold reduction in tumor
burden, thus highlighting the potent impact of peritoneal macrophages in promoting the
growth and survival of mesothelioma cells (Miselis et al.). In support of this studies,
Zeisberger et al. showed that CD1-nude mice receiving a subcutaneous injection of
murine F9 teratocarcinoma or human A673 rhabdomyosarcoma cells and treated with
CLIP had reduced infiltration of macrophages that resulted in slower tumor growth
(Zeisberger et al.). In addition, their results indicated that neutralizing Vascular
Endothelial Growth Factor (VEGF) and blocking angiogenesis with an anti-VEGF
antibody, SZH9, further decreased tumor burden (Zeisberger et al.). In mice injected with
the A673 cells, treatment with CLIP alone caused a 63% decrease in tumor volume while
treatment with SZH9 alone resulted in a 59% decrease (Zeisberger et al.). However, the
combined therapy resulted in a 74% reduction in tumor volume indicating that depleting
macrophages and blocking VEGF-dependent angiogenesis mas more effective in
inhibiting tumor development and progression (Zeisberger et al.). Lin et al. further
showed that mammary lesions in PyMT mice, a mouse model of breast cancer metastasis,
showed dense clusters of macrophages in the tumor stroma that preceded angiogenesis
(Lin, Li, et al.). Because the CSF-1R promoter is expressed in macrophages, CSF-a null
mutant mice showed a decrease in malignancy that was driven by a delay in angiogenesis
and a low density of macrophages (Lin, Li, et al.). In addition, the dense blood vessel
network did not develop in CSF-null mice as compared to WT mice, that developed
dense vessel networks in the mammary lesions as early as 8 weeks (Lin, Li, et al.).
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Myeloid-derived suppressor cells are another harmful immune cell population in the
tumor stroma that play a major role in tumor recurrence after treatment. Danilin et al.
showed that nude mice injected with MDA-MB-231 breast cancer cells into the
mammary fat pad had an abundance of MDSCs in the bone marrow (Danilin et al.). To
further elucidate the role of MDSCs, MDA-MB-231 cells were co-injected with naive
immature myeloid cells (iMCs) or tumor-induced MDSCs. Co-injection of MDA-MB231 cells and tumor-induced MDSCs increased the tumor volume by 2.7-fold and
simultaneously decreased the bone volume by 30% (Danilin et al.). These results
suggested that tumor-induced MDSCs created a microenvironment that favored growth of
breast cancer and loss of bone density. In support of these observations, athymic nude
mice that were co-injected with MDA-MB-231 cells in the left cardiac ventricle and
tumor-induced MDSCs in the tibia developed significantly larger tumors in the bone and
more osteolytic lesions compared to mice injected with iMCs, thus highlighting the
ability of MDSCs to promote bone destruction (Danilin et al.). In cell culture studies,
MDA-MB-231 cells co-cultured with tumor-induced MDSCs exhibited elevated
expression of the osteolytic factors, GLI2 and PTHRP in a transforming growth factor-β
(TGF-β) dependent manner (Danilin et al.). This study suggested that MDSCs utilize
their immunosuppressive function to promote tumor growth and drive breast-cancer
associated osteolysis. In addition, Nagaraj et al. used the synthetic triterpenoid, methyl
ester of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic (CDDO-ME; bardoxolone
methyl), a powerful activator of the transcription factor nuclear factor-erythroid 2-related
factor 2 (NRF2), that is involved in the upregulation of numerous anti-oxidant genes, to
target MDSCs in tumors (Nagaraj et al.). Because MDSCs promote tumor development
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by producing ROS, MDSCs were isolated from EL-4 thymoma tumor-bearing C7Bl/6
mice and treated with CDDO-Me (Nagaraj et al.). The viability of MDSCs was
significant impacted by CDDO-ME, and the levels of ROS were significant reduced
(Nagaraj et al.). In addition, MDSCs are known to inhibit antigen-specific CD8+ T cell
activity (Nagaraj et al.). Co-culturing MDSCs derived from EL-4 tumor bearing mice
with OT-1 T cells and CDDO-Me abrogated the suppressive activity of MDSCs on CD8+
T cells (Nagaraj et al.). In vivo, Nagaraj et al. found that CDDO-Me was able to inhibit
the suppressive activity of MDSCs on CD8+ T cells in mice implanted with EL-4, LLC
lung carcinoma, and MC38 colon carcinoma (Nagaraj et al.). Together these studies
established the impact of MDSCs in tumor development and progression. Targeting
MDSCs and inhibiting their immunosuppressive function may be a potent strategy to
promote CD8+ T cell-mediate cytotoxicity.
Finally, the immune-tolerant immune cell population, t-regulatory (Treg) cells, are
known to suppress pro-inflammatory responses and control the function and activity of
cytotoxic CD8+ T cells, an immune cell population that are potent tumor cell killers
(Antony et al.). Shifting the balance of these two adaptive immune cell populations can
facilitate a pro-inflammatory or anti-inflammatory immune responses (Antony et al.). An
abundance of Treg cells for example promotes an anti-inflammatory response whereas an
abundance of CD8+ T cells enhances a pro-inflammatory response (Antony et al.). In
addition, evidence showed that CD8+ T cell immunity is mediated by CD4+ T-helper (Th)
cells (Antony et al.).Under malignant conditions, an abundance of Treg cells correlated
with poor survival in hepatocellular carcinoma (HCC) patients (Fu et al.). In this study,
Fu et al. showed that circulating levels of Treg cells were significantly increased in HCC
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patients as compared to healthy individuals (Fu et al.). In addition, Treg cells
accumulated more in the tumor region as compared to adjacent healthy tissue and
increased in numbers with advancing cancer stage (Fu et al.). Further studies also showed
that Treg cells blocked the production of CD8+ T cells in HCC patients (Fu et al.).
Furthermore, Chen et al. generated a murine colon cancer cell line CT44, by stably
transfecting CT26 cells with EGFP protein fused to Hemophilius influenzae HA epitope.
Balb/c mice were subcutaneously injected with HA+ CT44 or HA- CT26 cells to study the
interaction between Treg cells and CD8+ T cells (M.-L. Chen et al.). Adoptive transfer of
naive CD8+ T cells with a transgenic TCR specific for Kd-restricted HA512-520 peptide
(HA specific CD8 cells) prior to tumor challenge of HA+ CT44 cells resulted in tumor
rejection, while HA- CT26 cells were not rejected (M.-L. Chen et al.). However, adoptive
transfer of HA specific CD8+ T cells and HA specific CD4+ Treg cells prior to CD44
tumor challenge showed that CD4+ Treg cells abrogated CD8-mediated tumor rejection
of HA+ CT44 cells (M.-L. Chen et al.). In this cohort, tumor development of HA+ CT44
cells closely mimicked the tumor development observed in CT26 tumor bearing mice
(M.-L. Chen et al.). In contrast, adoptive transfer of HA specific CD8+ T cells and HA
non-regulatory CD4+ T cells promoted tumor rejection of CT44 cells (M.-L. Chen et al.).
This study highlights the role of CD4+ cells in enhancing CD8+ T cell immunity, while
Treg cells interfere with CD+ T cell immunity.
Taken together, these studies suggest that targeting the tumor cells alone may not be
sufficient to effectively diminish tumor growth and that targeting the cells in the TME
that provide a permissive environment for tumor re-growth is warranted for more
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effective therapies. Modifying the TME may enhance response to therapy and improve
the patient’s prognosis.
1.6 MOUSE MODELS OF COLORECTAL CANCER
Animal models have proven to be a reliable experimental tool to recapitulate the early
and late stages of CRC. The ApcMin/+mouse has a germline mutation in the adenomatous
polyposis coli (APC) gene that is similar to the mutation that is found in 80% of sporadic
colon cancers in humans resulting in small intestinal and colonic tumors (A R Moser et
al.; A. R. Moser et al.; Daniel et al.; Rowan et al.). Familial Adenomatous Polyposis
(FAP) is an inherited form of colon cancer that is also a result of a mutation in the APC
gene (Rowan et al.). In the murine model, the multiple intestinal neoplasia (MIN) mutant
allele in the APC gene encodes a premature stop codon at 850 resulting in a truncated
polypeptide that lacks among others, the beta-catenin (β-catenin) binding site (A. R.
Moser et al.; Daniel et al.; Fearon and Vogelstein; Rowan et al.; A R Moser et al.). A
mutant copy of the APC gene in mice predisposes them to spontaneous development of
multiple adenomas residing predominantly in the small intestine and a few in the colon
(A R Moser et al.; A. R. Moser et al.; Daniel et al.; Fearon and Vogelstein; Rowan et al.).
The lifespan of the ApcMin/+mice is significantly reduced to approximately 15-20 weeks
as a results of acute anemia and intestinal obstruction by tumors (A. R. Moser et al.;
Daniel et al.; Fearon and Vogelstein; Rowan et al.; A R Moser et al.).
Mechanistically, the APC gene encodes the tumor suppressor protein that acts as an
antagonist to the WNT signaling pathway (Figure 1.4) (Zeisberger et al.). The APC
protein is a member of the β-catenin destruction complex. β-catenin and the WNT
signaling pathway regulate the maintenance, expansion, and differentiation of progenitor
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cells. β-catenin specifically regulates the gene transcription of c-myc, an oncogene, and
cyclin D, a regulator of cell cycle progression. When WNT signaling is inactive, the βcatenin destruction complex binds and degrades β-catenin by targeting it for
ubiquitination. Ubiquitinated β-catenin is sent to the proteasome to be further destroyed.
This results in silencing of c-myc and cyclin D. However, WNT signaling is activated
when WNT protein binds to its membrane-bound receptor, Frizzled. This binding results
in the dissociation of the β-catenin destruction complex, and an increase in β-catenin
levels in the cytoplasm due to evasion from degradation. β-catenin enters the nucleus and
transcriptionally activates genes such as c-myc and cyclin D (Grumolato et al.; Polakis;
Balkwill, Capasso and Hagemann; Novellasdemunt, Antas and Li). A mutation in the
APC gene causes aberrant WNT signaling because the β-catenin destruction complex is
no longer assemble due to the loss of β-catenin binding to APC. β-catenin escapes
degradation causing elevated levels of β-catenin in the cytoplasm leading to its entry into
the nucleus, which increases the transcription of c-myc and cyclin D. This occurs in the
transit amplifying zone of the intestines and causes the cell to lose control of cell growth,
differentiation, and survival which thereby permits polyps to form (Rennoll and Yochum;
Polakis; Novellasdemunt, Antas and Li; Grumolato et al.).

1.7 GOALS OF THE PROJECT
The overall goal of this project is to understand the role of the gut microbiome in
tumor development and response to 5-FU using the ApcMin/+mouse as a model of colon
carcinogenesis. We will test the hypothesis that folic acid from the diet and gut
microbiota modulates the response to 5-FU by modifying the gut microbiome
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composition, the tumor immune microenvironment, and metabolic composition in the
gut. In previous studies, ApcMin/+mice that were weaned to a folate deficient diet and
maintained on the diet throughout their lifetime showed decreased tumor burden and
improved response to 5-FU. However, given the significance of folate for healthy cellular
function, administering and maintaining a folate deficient diet may be detrimental to a
patient’s health. To develop a clinically relevant study, our goal is to determine if altering
folate concentrations prior to and during chemotherapy by administering a folate
deficient diet can enhance the efficacy of 5-FU therapy. We will use the ApcMin/+mice to
test this hypothesis. The experimental design is shown in Figure 3.1. Tumor bearing mice
were subjected to regular rodent chow, folate free, or folate replete diets and then
subjected to systemic therapy with 5-FU. We harvested the small intestines and colon and
assessed the tumor burden. Fecal pellets and blood were collected at several time points
to determine changes in the gut microbiota and hematopoietic parameters in response to
diet and 5-FU. We collected the cecum to assess changes in metabolites, such as short
chain fatty acids (SCFAs), in response to diet and chemotherapy. Finally, we analyzed
the tumor stroma to determine the changes in the TME in response to diet and 5-FU.
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Figure 1.1: 5-Year Survival Rate for Colorectal Cancer.
Cancer patients are initially diagnosed a stage, which
specifies the development and progression of their disease.
As the stage increases from localized to distant, the
severity of the disease increases which decreases the
patient’s survival outcome. Patients diagnosed at stage one,
where tumor growth is local to the originating tissue, have
the highest chance of five-year survival at 90%. As tumors
metastasize or establish in distance tissues, the chance of
five-year survival drastically decreases to 10%. This figure
highlights the importance of early detection and treatment
strategies as well as the devastating effects of late stage
CRC. Adapted from the NIH-NCI Surveillance,
Epidemiology, and End Results Program (SEER),
Cancer Stat Facts: Colorectal Cancer.
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Figure 1.2: 5-Fluorouracil and its Mechanism. 5-FU is the principal
therapy used for patients with CRC. 5-FU functions as an antimetabolite
drug where the C5 hydrogen molecule is replaced with a fluorine atom.
Thymidylate synthase functions to convert dUMP to dTMP. The
addition of a fluorine atom renders thymidylate synthase ineffective and
therefore inhibits the production of RNA and DNA. Adapted with
permission from Valoriote et al., Pharmacology and Therapeutics
1984.
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Figure 1.3: The Tumor Microenvironment. The TME is comprised of
a heterogeneous population of cells. Tumors are infiltrated with host
immune cells, cytokines, chemokines, and growth factors. These
molecules together help the tumor to prosper and rapidly divide. The
complexity of the TME makes it even more challenging to effectively
target CRC so that one drug is not able to successfully kill all cells
within the tumor. Adapted with permission from Quail and Joyce,
Nature Medicine 2013.
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Figure 1.4: The WNT Signaling Pathway. The WNT signaling
pathway is often compromised in CRC. The ApcMin/+ mouse contains a
mutation in the Apc gene, which produces a pre-mature stop codon and
a truncated protein. The Apc gene is a component of the β-catenin
destruction complex which functions to sequester, ubiquitinate, and
destroy β -catenin. The β - catenin destruction complex prevents β catenin from entering the nucleus to transcriptionally activate c-myc
and cyclin D. A mutation in the Apc gene causes the dissociation of the
β -catenin destruction complex and the release of β -catenin to enter the
nucleus to activate transcription. During CRC, excess amounts of β catenin are entering the nucleus to drive cell cycle progression and
promote tumorigenesis. Adapted with permission from Moon et al.
Nature Reviews Genetics 2004.
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CHAPTER 2
A FOLATE DEFICIENCY REDUCES TUMOR BURDEN IN ApcMin/+MICE
2.1 INTRODUCTION
Although 5-FU has been used in the clinical management of patients with CRC
for many decades, it is only mildly effective in 10% of patients (Johnston and Kaye;
Longley, Harkin and Johnston). As an added complication, the tumor is comprised of a
heterogeneous population of both neoplastic and non-neoplastic cells which makes
targeting the tumor cells challenging, and could increase the probability of tumor
recurrence. Residual tumor cells left after surgery or therapy can grow and reconstitute
the tumor, a major issue observed across numerous types of cancer. Therefore, effective
targeting and complete removal of cancer cells within the tumor might require multiple
treatments. Studies performed in patients and mice receiving a cocktail of therapies
reported enhanced tumor regression and prolonged survival (O’Shaughnessy et al.; Nie et
al.). In patients with advanced breast cancer receiving the combination therapy of
docetaxel with capecitabine had a 35% decrease in disease progression (docetaxel 4.2
months, docetaxel + capecitabine 6.1 months) (O’Shaughnessy et al.). In addition,
patients receiving combination therapy had a significant 23% reduction in risk of death,
and the mean survival increased from 11.5 months in patients receiving docetaxel alone
to 14.5 months in patients receiving docetaxel and capecitabine (O’Shaughnessy et al.).
Overall response rate improved from 30% to 42% when patients receiving combination
therapy (O’Shaughnessy et al.). In addition, Nie et al. showed that treatment of balb/c
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mice receiving a splenic injection of murine colorectal cancer cell line, CT26, with
adeno-associated virus-hepatocyte growth factor kringle 1 domain (AAV-HGFK1) and
recombinant adenovirus carrying p53 gene (Ad-p53) increased survival of mice and
blocked local and distal tumor growth (Nie et al.). AAV-HGFK1 is an antagonist for
hepatocyte growth factor (HGF) and interferes with angiogenesis (Nie et al.). Ad-p53
permits gene transfer to p53 tumor suppressor gene into cells to sensitize cancer cells to
treatment (Nie et al.). Adp53 has been shown to induce apoptosis and inhibit the growth
of tumor cells (Nie et al.). Mice receiving the combination therapy of AAV-HGFk1 and
Ad-p53 showed prolonged survival (63 days) compared to control untreated mice (21.5
days; p< 0.01) (Nie et al.). Single treatment of AAV-HGFK1 or Ad-p53 mildly
prolonged survival (AAV-HGFK1 27 days and Ad-p53 27.5 days, both P< 0.05) (Nie et
al.). Combination therapy also blocked primary tumor growth (spleen) and metastatic
spread (liver) as spleen and liver weights were significantly reduced in combination
therapy recipient mice as compared to control untreated mice 20 days after splenic
injection (P < 0.05) (Nie et al.). Subsequent studies indicate that this combination therapy
blocks angiogenesis, endothelial cell migration, and cellular proliferation (Nie et al.).
Tumors can also acquire resistance to 5-FU through many mechanisms.
Thymidine can be salvaged through thymidine kinase which undermines the TS
inhibition inflicted by 5-FU (N. Zhang et al.). Other mechanisms of resistance include
over-expression of TS through gene amplification and elevated folate pools (N. Zhang et
al.). These mechanisms of recurrence and resistance must be resolved in order to
effectively treat patients. Supplementing 5-FU with other therapeutic targets may be a
reliable method to enhance tumor response to treatment. Specifically, targeting TS with
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5-FU and removing folate, an essential cofactor, may render this enzyme ineffective,
promote genetic instability within the tumor, and increase the cytotoxicity of 5-FU.
In previous studies performed by Tucker et al. subjected three cohorts of ApcMin/+
mice to different diets: Rodent Chow (RC), Folate Free (FF), and Folate Replete
(FF+FA) (Tucker et al.). The FF and FF+FA diets contain 1% succinyl sulfathiazole
(SST), an antibiotic that inhibits folate producing bacteria. ApcMin/+ mice were weaned at
four weeks of age to RC, FF, or FF+FA. In cohort one, mice were treated with 5-FU (40
mg/kg) or phosphate buffered saline (PBS) from four to nine weeks to determine the
effect of dietary folate and 5-FU on tumor development. In cohort two, mice were treated
with 5-FU or PBS from nine to 14 weeks to determine the effect of dietary folate and 5FU on established tumors. In cohort three, mice were treated with 5-FU and PBS from
four to nine weeks, and then allowed to recover from 5-FU therapy until 15 weeks to
determine the effect of dietary folate on tumor recurrence post-therapy. In each cohort,
mice received three rounds of 5-FU (40mg/kg) or phosphate buffered saline (PBS)
administered five days a week with one week of rest in-between treatments (Tucker et
al.).
Results from cohort one indicate that ApcMin/+mice fed the FF diet had a
significant reduction in tumor burden at 10 weeks, while ApcMin/+ on the FF+FA diet
showed a modest decrease in tumor burden as compared to mice on the RC diet. Mice on
the FF diet had approximately a 50% reduction in tumor burden as compared to mice on
the FF+FA diet. When mice were treated with 5-FU, there was a further reduction in
tumor burden in mice on the FF diet as compared to mice on the RC or FF+FA diets
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(Figure 2.1B) (Tucker et al.). These data suggested that a FF diet attenuated tumor
growth and enhanced the cytotoxicity of 5-FU.
ApcMin/+mice in cohort two received three rounds of chemotherapy starting at nine
weeks and were euthanized at 15 weeks. These results showed that at 15 weeks, the
tumor burden of mice fed the FF and FF+FA diets were more similar, and significantly
lower as compared to mice fed the RC diet. When treated with 5-FU, mice on the FF diet
showed the most significant reduction in tumor burden as compared to mice on the RC or
FF+FA diets (Figure 2.1C) (Tucker et al.). These data suggested that although tumor
burden was significantly diminished in mice fed the FF or FF+FA diets as compared to
mice fed the RC diet, the difference in tumor burden between the two diets diminishes as
tumors increased in size. However, when combined with 5-FU therapy, a FF diet
enhanced therapeutic effects as indicated by reduced tumor burden.
In cohort three, the effect of folate deficiency on tumor recurrence following 5FU therapy was determined. 5-FU was administered at four weeks of age. Following
three rounds of chemotherapy, mice were given a six week recovery period and were
euthanized at 15 weeks to assess tumor burden (Figure 2.2A). The results showed that
tumor burden in mice on the RC and FF+FA diets that were given 5-FU rebounded to
similar levels as those in control mice that were treated with PBS and never received 5FU (Figure 2.2B-C). In contrast, tumor burden in mice that were treated with 5-FU on the
FF diet remained significantly lower as compared to untreated mice. These mice showed
a 75% reduction in tumor burden compared to their age-matched littermates that had
never received 5-FU (Figure 2.2D) (Tucker et al.). This data suggested that a FF diet
suppressed tumor development even after the removal of 5-FU. Thus, 5-FU administered
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under the RC and FF+FA diets appeared to be only cytostatic while administration in
combination with the FF diet was more cytotoxic.
In all of these studies, the FF and FF+FA diets contained 1% SST. Thus in
addition to reduced folic acid (FA) levels in the diet, folate production by gut bacteria
was also inhibited. Furthermore, this study only assessed the effect of the diets on
circulating folate levels, but did not consider their effects on the gut microbiome
composition or the potential role of the gut microbiota on tumor development or response
to therapy. In addition, this study was conducted in mice up to 15 weeks of age.
The overarching goal of this study is to determine the effect of folate deficiency
and the role of the gut microbiome on tumor response to therapy. In this chapter, I will
establish the baseline parameters with respect to tumor burden, blood parameters, and
weights as well as collect pellets for analysis of changes in the gut microbiome when fed
the different diets up to 18 weeks of age, when subsequent studies will be conducted.
Thus, we conducted experiments as outlined in Figure 2.3. ApcMin/+ mice (38)
were purchased from Jackson Laboratory (Bar Harbor, ME) at four weeks. Mice were
immediately placed on RC, FF, and FF+FA diets. Fecal pellets and serum samples were
collected every four weeks to assess changes in the gut microbiome and hematopoietic
parameters. Mice were euthanized at 18 weeks to harvest essential organs for analysis
and assessment of tumor burden.
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RESULTS
2.2A: FOLATE DEFICIENT DIET IMPROVED PARAMETERS IN TUMORBEARING MICE
ApcMin/+mice typically display decreased body weight, enlarged spleens, and
anemia as they succumb to CRC. Measurements of hematocrit (HCT), hemoglobin
(HGB), and red blood cells (RBCs) typically provide a measure of the extent of anemia. I
assessed these parameters to characterize the effects of folate deficiency on tumor
development, progression, and overall health of the mice.
The results showed that in general throughout the 18 weeks, ApcMin/+mice fed the
FF diet displayed fewer symptoms of CRC as compared to mice on the RC and FF+FA
diets. Mice fed the FF diet consistently had higher body weights as compared to mice fed
the RC and FF+FA which consistently showed lower body weights. In fact, mice on the
FF+FA diet succumbed to the disease rapidly as indicated by a steep decline in body
weight starting at 12 weeks (Figure 2.4A). Due to their severe weight loss, mice on the
FF+FA diet were euthanized pre-maturely at 15 weeks.
An enlarged spleen is commonly observed in ApcMin/+mice with a high tumor
burden. As CRC progresses and symptoms worsen, the spleen weight typically increases.
Spleen weight was reduced significantly in mice fed the FF diet as compared to mice fed
the RC and FF+FA diets. Replenishing FA, as observed in the FF+FA diet, caused
enlargement of the similar to that observed in mice fed the RC diet. This suggested that
FA may be a critical component in promoting systemic inflammation (Figure 2.5A).
Mice fed the RC diet exhibited a steady decline in HCT, HGB, and RBCs starting
at 12 weeks, a characteristic of ApcMin/+mice as they age. Mice fed the FF diet showed
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improvement in hematopoietic parameters as compared to mice fed the RC diet, as they
maintained healthy measures of HCT, HGB, and RBCs throughout the entire 18 weeks.
On the other hand, mice on the FF+FA diet declined rapidly starting at seven weeks, just
four weeks after being placed on the diet (Figure 2.5B-D). Although the hematopoietic
parameters between RC and FF+FA mice were not similar, it was evident that
replenishing the diet with folic acid had profound negative effects on systemic health.
Overall, a FF diet reduced anemia, a major symptom of CRC in ApcMin/+mice.

2.2B: FOLATE DEFICIENCY REDUCED TUMOR BURDEN
Tumor burden was assessed by counting the number of adenomatous polyps
present in the small intestines and colon. Mice fed the RC and FF diets were euthanized
at 18 weeks, while mice fed the FF+FA diet were euthanized at 15 weeks. Tumor burden
was significantly reduced when mice were fed the defined diets, FF and FF+FA.
However, the mice fed the FF and FF+FA at 18 and 16 weeks of age showed no
significant difference in tumor burden (Figure 2.6A). In addition, tumor size was not
significantly altered by the dietary alterations (Figure 2.6B). This data suggested that the
defined diets suppressed tumor development in ApcMin/+ mice. Whether this suppression
is due to the inhibition of bacterial folate production by SST or the defined diets is
unknown and still needs to be determined.

2.3 SUMMARY AND DISCUSSION
The results from this study showed that a FF diet protected mice from typical
CRC symptoms observed as tumor progress in ApcMin/+mice as indicated by an increase
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in body weight, a decrease in spleen weight, and an improvement in hematopoietic
parameters. When folic acid was added back into the diet, adverse effects were observed
in the mice. Overall health of mice fed the FF+FA diet declined rapidly as indicated by a
steep decrease in body weight, an increase in spleen weight, and a decrease in
hematopoietic parameters. In fact, mice fed the FF+FA diet became very ill and had to be
euthanized three weeks earlier (15 weeks of age), highlighting the negative systemic
effects of elevated FA in ApcMin/+mice.
Because tumor burden was assessed at a late stage in tumor development, the
results showed no significant effect of FA on tumor burden in the defined diets. However,
it is important to note that tumor burden was assessed at different times; due to the fact
that mice fed the FF+FA diet had to be sacrificed earlier. In support of this notion,
previous studies showed a reduction in tumor burden in mice on the FF diet, and a
partially restored phenotype when FA was added back into the diet (Tucker et al.).
However, these mice were euthanized at 10 weeks of age. When previous investigators
assessed tumor burden at 15 weeks of age, they found that mice on FF and FF+FA diets
showed a similar tumor burden. This data together suggests that a FF diet suppresses
tumor development at early stages to tumorigenesis. However, as the mice continue to
age and tumors continue to develop, the FF diet becomes less effective. Based on
previous studies and experiments, tumor burden is unlikely to be changed if mice fed the
FF+FA diet lived to the expected 18 weeks. Although restoring FA did not seem to
significantly affect tumor burden, mice fed the FF+FA diet were very ill and anemic
compared to mice fed the RC and FF diets.
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In previous studies, Tucker et al. showed that tumor burden in 15 week old mice
fed the FF and FF+FA diets were comparable suggesting that folate deficiency may not
affect tumor initiation but may affect tumor progression (Tucker et al.). Our results
suggest that at 18 weeks of age, tumors that were initiated in the mice fed the FF diet at
four weeks eventually progress to the same size as those mice fed the FF+FA diet, even
in the absence of folate from the gut microbiome that is inhibited by SST present in the
diet. However, tumor burden in mice fed the FF and FF+FA diets were much lower than
those found in mice fed the RC diet.
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Figure 2.1: The Role of Folate on Tumor Development and Response to
5-FU. Previous studies by Tucker et al. examined the role of folate deficiency
in tumor response to 5-FU. ApcMin/+ mice were weaned to rodent chow, folate
free or folate replete diets. A. Cohort one determined the impact of folate
deficiency and 5-FU on tumor development whereas cohort two determined
the impact of folate deficiency and 5-FU on the regression of tumors that are
already established. Tumor burden in (B) cohort one and (C) cohort two
showed that manipulating folate levels reduced tumor burden and treatment
with 5-FU further reduced tumor burden. (* p< 0.05, ** p< 0.01, *** p<
0.001). Adapted from Tucker et al., Cancer Letters 2002.
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Figure 2.2: The Role of Folate on Tumor Recurrence after Treatment
with 5-FU. Previous studies by Tucker et al. examined the role of folate
deficiency in response to 5-FU in ApcMin/+ mice that were weaned onto
folate free and folate replete diets. A. Cohort three determined the impact of
folate levels on tumor recurrence following the removal of 5-FU therapy.
The results showed that tumor burden rebounded to untreated levels in
ApcMin/+ mice fed the (B) rodent chow and (C) folate replete diets.
However, the tumor burden in ApcMin/+ mice fed the (D) folate deficient diet
remained low and similar to ApcMin/+ mice that received chemotherapy and
were euthanized immediately after treatment. (* p< 0.05, ** p< 0.01, ***
p< 0.001, ns not significant). Adapted from Tucker et al., Cancer Letters
2002.
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Figure 2.3: Mouse and Spleen Weights and Hematopoietic Parameters.
A. To establish a baseline for subsequent studies, ApcMin/+ mice were
weaned onto rodent chow (RC), Folate Free (FF), and Folate Free plus 6
ppm Folic Acid (FF+FA) diets. The FF and FF+FA diets contained 1%
succinyl sulfathiazole (SST). Fecal pellets were collected at the designated
time points. Mouse weights of ApcMin/+ mice fed the (B) RC (red), FF
(purple), and FF+FA (blue) diets throughout the experiment and (C) at
sacrifice. D. Spleen weights in ApcMin/+ mice fed the RC, FF, and FF+FA
diets. Hematopoietic parameters, (E) hematocrit (HCT), (F) hemoglobin
(HGB), and (G) red blood cells (RBCs), in ApcMin/+ mice fed the RC, FF,
and FF+FA diets. Yellow bars indicate of the normal healthy range of these
parameters. (* p< 0.05, ** p< 0.01, *** p< 0.001 ns not significant).
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Figure 2.4: Tumor Burden. Tumor burden was assessed by determining
the number of polyps present in the small intestines and colon. A. Total
tumor burden is reduced in ApcMin/+ mice fed the FF and FF+FA diets
relative to mice fed the RC diet. B. Similar reduction in tumor burden
was observed when we examined only tumors that are larger than 1mm.
(* p< 0.05, ** p< 0.01, *** p< 0.001, ns not significant).
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CHAPTER 3
TRANSIENT MODIFICATIONS OF THE GUT MICROBIOTA THROUGH A
FOLATE DEFICIENT DIET ENHANCES THE CYTOTOXIC EFFECTS OF 5FLUOROURACIL IN ApcMin/+MICE
3.1 INTRODUCTION
Folate is an essential nutrient for a healthy individual. Reducing or eliminating
folate can be detrimental to a healthy human and may lead to neoplastic transformation
(Duthie). Folate is important for red blood cell formation as well as in the synthesis of
amino acids and nucleotides. Folate plays a critical role in the catalysis by thymidylate
synthase and is essential for DNA synthesis in actively proliferating cells. However,
folate provides the essential co-factor required for TS function and its presence in the gut
may enhance the cellular proliferation of tumor cells and therefore, may exacerbate CRC
development and progression (Ryan and Weir). Eliminating folate in the gut during
tumorigenesis may suppress tumor development and progression, and improve patient
outcome. Because folate functions as a double-edged sword, manipulating its levels must
be managed very carefully at the appropriate time.
In previous studies (Tucker et al.) and in the previous chapter, mice were weaned
to the different diets and kept on the diets throughout the study. To develop a clinically
relevant strategy, my goal was to target the gut microbiota just prior to administration of
chemotherapy to determine if folate depletion will render 5-FU more cytotoxic to tumors
while protecting against drug induced toxicities. The experimental design that was used is
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in Figure 3.1. Forty C57Bl/6 wild type (WT) and sixty ApcMin/+ littermates were
purchased from Jackson Laboratory (Bar Harbor, ME) at four weeks of age. The mice
were immediately placed on the RC diet upon arrival. Tumors were allowed to develop
until the mice were 10 weeks of age. At 10 weeks, WT and ApcMin/+mice were randomly
assigned to one of the following six experimental groups based on their diet and
treatment: 1) Rodent Chow + PBS, 2) Rodent Chow + 5-FU, 3) Folate Free + PBS, 4)
Folate Free + 5-FU, 5) Folate Replete + PBS, and 6) Folate Replete + 5-FU. Phosphate
buffered saline (PBS) was used as the non-treatment control. Mice were maintained on
their respective diets for three weeks to allow the gut microbiota to adapt to the diets. At
13 weeks, mice were subjected to systemic treatment with 5-FU as described in Chapter
2. Briefly, five doses/week of 5-FU (40mg/kg) or PBS were administered by
intraperitoneal injection. Chemotherapy was administered for one week followed by a
rest week, for a total of three rounds. Fecal pellets and sera were collected weekly
throughout the experiment to assess changes in the gut microbiota and hematopoietic
parameters. Mice were euthanized at 18 weeks and essential organs were harvested for
analysis of tumor burden and immune cell infiltration.

RESULTS
3.2A: A FOLATE DEFICIENT DIET ENHANCED OVERALL HEALTH OF APCMIN/+
MICE
WT mice fed the RC diet maintained a relatively consistent body weight. When
subjected to 5-FU, the mice lost weight after the treatment week but recovered during the
rest week. Overall, the body weight of WT mice on the RC diet receiving 5-FU or PBS
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did not fluctuate drastically and 5-FU treated mice recovered during the rest week
suggesting no serious impact of 5-FU or PBS (Figure3.2A). WT mice fed the FF and
FF+FA diets showed a gradual increase in body weight. Similar to mice fed the RC diet,
mice on the FF and FF+FA diets lost weight when subjected to 5-FU but recovered
during the rest week (Figure 3.2C,E). The diseased, ApcMin/+mice, responded quite
differently. During three rounds of chemotherapy, the overall body weight of
ApcMin/+mice was consistently lower than their WT counterparts as tumor development
progressed. ApcMin/+mice fed the RC diet maintained a relatively consistent body weight
when subjected to PBS and 5-FU (Figure3.2B). ApcMin/+ mice lost some weight during
treatment with 5-FU but recovered during the rest week. However, ApcMin/+mice fed the
FF and FF+FA diets showed a reduction in body weight over time as tumors develop in
these mice. When subjected to 5-FU, these mice showed dramatic improvements in body
weight (Figure3.2 D, F). In addition, ApcMin/+mice fed the FF diet showed the greatest
increase in body weight and had fewer fluctuations in body weight than ApcMin/+mice fed
the FF+FA diet. Specifically, ApcMin/+mice fed the FF+FA diet and treated with 5-FU
reported large losses in body weight during treatment with chemotherapy (Figure 3.2D,
F).
The final body weights of mice at the end of the study provided an indication of
the overall effects of CRC, diet, and 5-FU. WT mice fed the RC, FF, and FF+FA diets
showed no significant difference in body weight at sacrifice (RC 28.45 ± 2.16, FF 29.40
± 1.82, FF+FA 30.82 ± 3.82). However, following three rounds of chemotherapy, WT
mice treated with 5-FU had lower body weights compared to their PBS treated controls
(RC 5-FU 26.11 ± 1.49, FF 5-FU 25.66 ± 0.82, FF+FA 5-FU 25.10 ± 1.74) (Figure3.3A).
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WT mice had consistently higher body weights relative to ApcMin/+littermates (WT RC
28.45 ± 2.16 versus ApcMin/+ RC 24.25 ± 2.61; WT FF 29.40 ± 1.82 versus ApcMin/+ FF
20.99 ± 2.48; WT FF+FA 30.82 ± 3.82 versus ApcMin/+ FF+FA 20.31 ± 2.38). The
ApcMin/+mice fed the FF and FF+FA diets had significantly lower body weights as
compared to mice fed the RC diet (RC 24.25 ± 2.61; FF 20.99 ± 2.48; FF+FA 20.31 ±
1.28). However, when subjected to 5-FU, the body weights significantly increased in
mice fed the FF and FF+FA diets, with mice fed the FF diet showing the highest body
weight (RC 24.55 ± 1.55; FF 25.14 ± 1.35; FF+FA 23.57 ± 2.38) (Figure 3.3B).
The average spleen weight was very small in WT mice fed the RC, FF, and
FF+FA diets (RC .073 ± .0067; FF .078 ± .0110; FF+FA .0760 ± .0195) with a
significant increase in RC but not FF and FF+FA diets when treated with 5-FU (RC .159
± .0661, p=0.003; FF .102 ± .0753, p=0.52; FF+FA .126 ± .0907, p=0.29) (Figure 3.3C).
On the other hand, the ApcMin/+mice had enlarged spleens (RC .500 ± .0822; FF .229 ±
.1476; FF+FA .314 ± .1492). ApcMin/+mice fed the RC diet and treated with 5-FU showed
a significant reduction in spleen weight as compared to untreated mice fed the RC diet
(RC .289 ± .1199, p=0.0004). Interestingly, ApcMin/+mice fed the FF diet had smaller
spleens that were not altered when treated with 5-FU (FF 5-FU .241 ± .0983, p=0.84).
Lastly, the ApcMin/+ mice fed the FF+FA diet had a lower spleen weight as compared to
ApcMin/+ mice fed the RC diet that increased when treated with 5-FU (FF+FA 5-FU .440
± .1657; p=0.11) (Figure 3.3D). A decrease in the spleen weight among the ApcMin/+mice
on a FF diet suggested reduced inflammation and potentially slowed disease progression
that was further improved upon treatment with 5-FU. Interestingly, mice fed the FF+FA
diet had lower spleen weights that were dramatically enlarged upon treatment with 5-FU.
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As seen in chapter two, mice weaned to the FF+FA diet displayed enlarged spleens. This
difference in weights may be due to the extended time that mice were fed the FF+FA diet
in the previous study; that is, they were weaned to the diet at four weeks of age and kept
on the diet until the end of the study. This data in the currently study perhaps suggests
that FA may cause adverse effects in mice that are receiving 5-FU.
As described in chapter two, hematopoietic parameters are useful tools to assess
the presence of anemia in mice with developing CRC. The data showed that in WT mice
on the RC diet, these parameters remained in the health range expected for HCT, HGB,
and RBCs. When WT mice were fed the FF or FF+FA diet, these hematopoietic
parameters also remained in the healthy range. However, when WT mice were treated
with 5-FU, these parameters decreased but recovered to normal or healthy ranges by the
end of the study (Figure3.4A-C). The ApcMin/+ + mice responded differently. ApcMin/+mice
fed the RC diet showed a gradual decline in HCT, HGB, and RBCs throughout their
lifetime. When treated with 5-FU, the mice exhibited healthy measures in these
parameters following one round of 5-FU. ApcMin/+mice on FF and FF+FA diets showed a
steeper decline in these hematopoietic parameters rendering these mice highly anemic.
However, upon treatment with 5-FU, ApcMin/+mice on a FF diet quickly regained healthy
ranges following one round of chemotherapy, similar to ApcMin/+mice fed the RC diet.
The ApcMin/+mice on a FF+FA diet on the other hand, required three rounds of
chemotherapy to recover to a healthy range in these hematopoietic parameters (Figure
3.4A-C). These data suggest that administering 5-FU in the presence of a FF diet
improved the health of ApcMin/+mice, perhaps as a consequence of reduced tumor burden
due to enhanced efficacy of 5-FU. In addition, ApcMin/+mice on the FF+FA diet required
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three times the dosage of 5-FU before symptoms improved implying that FA in the diet
hinders 5-FU from functioning effectively. These data also strongly correlates with a
reduction in spleen weight observed in ApcMin/+ mice fed the FF diet and treated with 5FU and an increase in spleen weight in ApcMin/+mice fed the FF+FA diet and treated with
5-FU.

3.2B: FOLATE DEFICIENCY ENHANCED THE ANTI-TUMOR EFFICACY OF 5-FU
Assessment of tumor burden after systemic 5-FU therapy of mice in the different
diets revealed differences in tumor response to therapy. When ApcMin/+mice were
switched to the FF or FF+FA diets at 10 weeks of age after tumors were established,
there was no significant difference in tumor burden between mice fed the RC, FF, and
FF+FA diets. The average tumor burden for mice fed the RC, FF, and FF+FA diets was
statistically similar (RC 69.80 ± 18.66; FF 67.10 ± 27.36; FF+FA 60.44 ± 15.08)
(Figure3.5D). When these mice were treated with 5-FU, the mice fed the RC and FF+FA
diets exhibited a mild reduction in tumor burden of approximately 40% and 30% as
compared to the untreated mice (RC 5-FU 44.60 ± 17.24, p=0.006; FF+FA 5-FU 42.20 ±
21.27, p=0.045) (Figure3.5A-B). However, mice fed the FF diet and treated with 5-FU
had a greater reduction in tumor burden by approximately 70% (FF 5-FU 22.40 ± 13.30,
p=0.0005) (Figure3.5C). Compared to mice fed the RC and FF+FA diets, mice fed the FF
diet showed a 50% greater reduction upon treatment with 5-FU (Figure 3.5E). This data
strongly suggests that supplementing mice with a FF diet while receiving 5-FU was
sufficient to enhance the anti-tumor efficacy of 5-FU. Therefore, under conditions where
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dietary folate is diminished and folate production by the gut microbiota is inhibited, 5-FU
is more potent at reducing tumor burden in ApcMin/+ mice.

3.3 SUMMARY AND DISCUSSION
The results from this study showed that the effect of 5-FU on ApcMin/+ mice can
be influenced by folate levels. Specifically, mice fed the FF diet and treated with 5-FU
showed fewer fluctuations in body weight suggesting some protection against 5-FU
toxicity while ApcMin/+mice fed the FF+FA diet and treated with 5-FU showed greater
body weight loss. In addition, ApcMin/+mice fed the FF diet and treated with either PBS or
5-FU had smaller spleens suggesting that removal of FA in the diet reduced systemic
inflammation. ApcMin/+mice fed the FF+FA diet and treated with PBS also Hs smaller
spleens; however, treatment with 5-FU caused enlargement of the spleen. This
observation may suggest that SST may function to suppress systemic inflammation in
ApcMin/+mice fed the FF and FF+FA diets; however, upon treatment with 5-FU, mice fed
the FF diet were protected against 5-FU toxicity, but restoring folate into the diet
exacerbated 5-FU effects. The data also showed that FA supplementation with 5-FU
promoted inflammation, which was consistent with the effects on the hematopoietic
parameters. In the data analyzing HCT, HGB, and RBCs, ApcMin/+mice on the FF and
FF+FA diets and treated with PBS became anemic. A FF diet alone was not sufficient to
reduce anemia in ApcMin/+mice; however, when treated with 5-FU, mice fed the FF diet
were able to regain healthy levels of all three hematopoietic markers after only one round
of 5-FU. The mice fed the FF+FA diet on the other hand, required three rounds of 5-FU
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to regain healthy levels of HCT, HGB, and RBCs. These results suggest that a FF diet
can protect against hematopoietic toxicity from 5-FU.
The improved hematopoietic parameters in ApcMin/+mice fed the FF diet
correlated with decreased tumor burden. Control mice on RC, FF, and FF+FA diets
treated with PBS showed no significant differences in tumor burden. This data is
suggestive that the tumors were established at 10 weeks of age, altering the diet did not
impact tumor progression. However, upon treatment with 5-FU, mice that were fed the
FF diet showed a much larger reduction in tumor burden as compared to mice that were
fed the RC or FF+FA diets.
The results further showed that altering the gut microbiota did not impact the
development of already established tumors. Control mice on the FF and FF+FA diets had
similar body and spleen weights, and hematopoietic parameters. Despite this, there were
striking differences in their response to 5-FU. The results thus far have shown that folate
deficiency and 5-FU together protects against weight loss, alleviates inflammation as
indicated by a reduced spleen weight, protects against hematopoietic toxicity, and
reduces tumor burden. In the next chapter, we will examine the potential mechanisms
underlying these observations.
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Figure 3.1: Experimental Design for the Role of Folate on 5Fluorouracil in ApcMin/+ Mice. This diagram shows the timeline for the
experiment to determine the impact of folate deficiency on the anti-tumor
efficacy of 5-FU in ApcMin/+ mice. WT and ApcMin/+ mice were purchased
from Jackson Laboratory. Upon arrival at our facility, mice were placed
on the RC diet. At 10 weeks, mice were randomly assigned to RC, FF, or
FF+FA diets. At 13 weeks, mice started their three rounds of 5-FU or
PBS systemic therapy with a rest week in between the treatment weeks.
Fecal pellets were collected as indicated below and mice were euthanized
at 18 weeks.
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Figure 3.2: Mouse Weight throughout 5-FU Exposure. The impact of 5FU was assessed by monitoring the body weight throughout treatment.
Results showed changes in the body weights of WT mice fed the (A) RC,
(C) FF, and (E) FF+FA diets treated with PBS and 5-FU. These results also
show changes in body weight of ApcMin/+ mice fed the (B) RC, (D) FF, and
(F) FF+FA diets treated with PBS (blue) and 5-FU (red).
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Figure 3.3: Mouse and Spleen Weight. Mouse weight of (A) C57Bl/6 WT
and (B) ApcMin/+ mice fed the RC, FF, and FF+FA diets and treated with
PBS (blue) or 5-FU (red). Spleen weight of (C) C57Bl/6 and (D) ApcMin/+
mice fed the RC, FF, and FF+FA diets and treated with PBS (blue) or 5-FU
(red). (* p< 0.05, ** p< 0.01, *** p< 0.001).
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Figure 3.4: Hematopoietic Parameters. The levels of Hematocrit (HCT),
hemoglobin (HGB), and red blood cells (RBCs) in mice fed the (A) RC, (B)
FF, (C) FF+FA diets throughout the experiment. Results in the WT mice are
indicated by solid lines and ApcMin/+ mice are indicated by dashed lines. Blue
lines are representative of PBS treated mice and red lines are indicative of 5FU treated mice. The yellow bars are indicative of the normal healthy range
of these parameters.
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Figure 3.5: Tumor Burden. A-C Tumor burden in ApcMin/+ mice fed the (A)
RC, (B) FF, and (C) FF+FA diets treated with PBS (blue) and 5-FU (red).
Tumor burden in ApcMin/+ mice fed the RC, FF, and FF+FA diets and treated
with (D) PBS and (E) 5-FU. (* p< 0.05, ** p< 0.01, *** p< 0.001, ns not
significant).
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CHAPTER 4
A FOLATE DEFICIENTCY ALTERS THE GUT MICROBIOTA AND PROMOTES
TUMOR REGRESSION
4.1 INTRODUCTION
The results from chapter three suggest that a folate deficiency can enhance the
cytotoxic effects of 5-FU. We hypothesized that a potential underlying mechanism might
be that the FF diet with 1% SST might alter the gut microbiota to create a less
inflammatory microenvironment that might facilitate tumor suppression and regression.
Previous studies have shown that the gut microbiota is altered in CRC to promote and
exacerbate tumorigenesis (Rubinstein et al.; Kostic, Chun, et al.; Castellarin et al.; Kostic,
Gevers, et al.; Zackular, Baxter, Iverson, et al.; Zackular, Baxter, Chen, et al.). In
addition, previous studies have also shown that the gut microbiota may determine the
efficacy and toxicity of chemotherapy suggesting that targeting and manipulating the gut
microbiota may be a powerful tool to enhance therapeutic efficacy against CRC (Yu et
al.; Levy et al.; Scott et al.; Soveri et al.; Alexander et al.; Iida et al.). The gut microbiota
is comprised of numerous bacterial species, some of which may be beneficial or harmful.
It is important to identify which gut microbial populations are changing in response to
diet to elucidate how these microorganisms may promote or suppress tumor development
or therapeutic efficacy.
Therefore, the goal of this chapter is to determine the changes in the gut microbial
populations as a consequence of dietary manipulation. Identifying the bacterial
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populations and species that are altered might provide insight into cellular and molecular
events occurring at the tumor microenvironment.
To determine the gut microbiome composition, we isolated genomic DNA from
fecal pellets at different time points in the study. To assess changes in the gut microbiota
in response to diet, our analysis will include WT mice fed the RC diet and ApcMin/+ mice
fed the RC, FF, and FF+FA diets.
We hypothesized that changing the diets from RC to FF or FF+FA might alter the
gut microbiota to enhance 5-FU efficacy and cytotoxicity to tumors. Genomic DNA
isolated from fecal pellets was prepared for 16S ribosomal sequencing using Next
Generation Sequencing (NGS). Samples were sent to the Heflin Genomics Core at the
University of Alabama, Birmingham. R1 and R2 FastQ files were retrieved and analyzed
using Quantitative Insights Into Microbial Ecology (QIIME) Analysis Software.

RESULTS
4.2A: A FOLATE DEFICIENT DIET WITH 1% SST SIGNIFICANTLY ALTERED
THE GUT MICROBIOME COMPOSITION
16S ribosomal sequencing revealed significant changes in the gut microbiome
composition in response to dietary manipulation. Alpha diversity is a statistical analysis
indicating the microbial diversity present within a sample. It provides valuable
information regarding species richness, or the number of species present within a sample,
and species evenness, or the relative abundance of different species within a sample. A
rarefaction plot shows the number of species as a function of the number of samples and
is a powerful tool to assess species richness. The major characteristic of a rarefaction
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curves is a steep initial slope that eventually plateaus. This steep initial slope represents
of the most common species that are present while the plateau represents the rare species
within the sample. A rarefaction plot that plateaus early suggests that a particular sample
has less species richness. The rarefaction plot (Figure 4.1B) shows that WT and
ApcMin/+mice fed the RC diet both had high species richness. When mice were switched
to the defined diets, FF and FF+FA, there was a significant decrease in species richness.
The rarefaction plots were quantified to show the number of observed operational
taxonomic units (OTUs) within each sample (Figure 4.1A). This data showed that WT
and ApcMin/+ mice fed the RC diet had no significant difference in species richness
suggesting that CRC does not significantly impact the number of species present within a
sample. However, when mice are switched to the FF and FF+FA diets, the number of
species present within the samples significantly decreases suggesting that the diets are
largely responsible for species richness and altering the abundance of microbes in the gut.
Beta diversity is a descriptive interpretation that shows the diversity of a set of
samples to other samples within the dataset. In microbiome datasets, beta diversity is
often summarized in a principal component analysis (PCoA) plot, which transforms a
number of correlated variables into a small number of uncorrelated variables. PCoA plots
are typically two or three-dimensional where each dimension accounts for a principal
component. The first principal component usually accounts of the most variability within
the data and the subsequent principal components account for the remaining variability
present in the dataset. PCoA plots can also be unweighted or weighted. An unweighted
PCoA plot is a qualitative interpretation that only accounts for the absence or presence of
species whereas the weighted PCoA plot is a quantitative interpretation that accounts for
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the relative abundance of species. The four groups used in this analysis were WT mice
fed the RC diet, and ApcMin/+ mice fed the RC, FF, and FF+FA diets. In the unweighted
PCoA plot, there is clear separation between all four groups suggesting that the microbes
present in the gut were distinct from each other. This data strongly suggests that WT and
ApcMin/+mice have significant differences in the composition of microbes present in their
gut. In addition, this data also shows that the FF and FF+FA diets dramatically altered the
species present in the gut microbiota (Figure 4.1C). In the weighted PCoA plot, where the
abundance of bacterial species is accounted for, there was no clear separation between the
groups suggesting that the relative abundance of specific taxa is not driving this effect
(Figure 4.1D).
When analyzing gross compositional shifts at the phylum level, there was a
significant expansion of Firmicutes and reduction of Bacteroidetes in ApcMin/+mice fed
the FF and FF+FA diets (Figure 4.2A). The ratio of Bacteroidetes to Firmicutes
significantly decreased in ApcMin/+mice fed the FF and FF+FA diets as compared to WT
and ApcMin/+mice fed the RC diet (Anova P=0.04) (Figure 4.2B). When analyzing the
gross compositional changes at the family level, there was a significant loss of the
Bacteroidetes S24-7 group in mice fed the FF and FF+FA diets. Furthermore, in mice fed
the FF and FF+FA diets, there was an expansion in members of the Firmicutes family
Ruminococcus, and an unclassified family within Clostridiales class (Figure 4.2C; Figure
4.3D-E). The S24-7 family population was significantly diminished, and the
Coriobacteriaceae family and Lactobacillus genus populations expanded in mice fed the
FF and FF+FA diets (Figure 4.3A-C). It is interesting to note that these changes in the gut
microbiome composition occurred in mice fed the FF and FF+FA diets, despite the
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addition of folate in the FF+FA diet suggesting that these may be a result of the defined
diets or the presence of the antibiotic, SST. It would be interesting to determine if such
changes will occur in the absence of the antibiotic.
Although many changes were found ApcMin/+mice fed the FF and FF+FA diets,
there were some changes observed only in ApcMin/+mice fed the FF diet. When folate was
reconstituted in the FF+FA diet, some bacterial populations were present at similar
abundances as compared to ApcMin/+ mice fed the RC diet. ApcMin/+mice fed the RC and
FF+FA diets showed low levels of the Firmicutes family, Ruminococcus sp., and an
unclassified family within the Costridiales class. However, ApcMin/+mice fed the FF diet
had higher levels of these populations (Figure4.3 D-E). This data suggests that although
the majority of changes observed in the gut microbiota are driven by the FF and FF+FA
diets, FA in the diet still modifies some bacterial populations in the gut.

4.3 SUMMARY AND DISCUSSION
The results from these studies examining the impact of diet on the gut
microbiome composition revealed vast differences in alpha and beta diversity. Mice fed
the FF and FF+FA diets showed a significant reduction in species richness and diversity.
The unweighted PCoA plot showed a clear distinction amongst the four experimental
groups, WT RC, ApcMin/+ RC, ApcMin/+ FF, and ApcMin/+ FF+FA, suggesting that the
differences were primarily driven by the species present within the communities among
the different cohorts. In addition, the weighted PCoA plot, which accounts for the relative
abundance of each taxa within the communities, displayed no separation among the four
groups. This suggests that the differences were not driven by the relative abundance of
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specific taxa. These principal component plots strongly suggest that perhaps the microbes
populating the gut, as a consequence of diet may play a major role in tumor response to
therapy. The weighted PCoA plot highlights how the abundance of microbes populating
the gut is not playing a role in tumor response to therapy. In support of this notion, the
Bacteroidetes S24-7 population was nearly eliminated in ApcMin/+ mice fed the FF and
FF+FA diets, an effect that is unique and novel.
The S24-7 family is an unculturable family belonging to the Bacteroidetes
phylum that has recently gained attention in the field. This bacterial group is generally
present in 20% of humans and 50% of mice. Genomic characterization reveals that S24-7
is generally a beneficial group of bacteria, although some members down regulate the
immune system. They are capable of producing anti-inflammatory short chain fatty acids
(SCFAs) acetic acid, propionic acid, and succinic acid as well as folate, thiamine,
riboflavin, niacin, pantothenate, and biotin. In addition, evidence shows that S24-7
contains proteins to provide protection against oxidative stress. Finally, it is known that
some members of the S24-7 family metabolize host glycans which can potentially impact
gut inflammation by influencing gut permeability (Ormerod, Wood, Lachner, Gellatly,
Daly, Parsons, Dal’Molin, et al.). Perhaps, the diverse functions of S24-7 may influence
the concentration of SCFAs in the gut and reduce the abundance of folate in the gut. In
addition, perhaps the reduction in S24-7 in mice fed the FF and FF+FA diets may
increase oxidative stress to tumor cells to promote cell death. Depletion of S24-7 may
also aid in reducing gut inflammation and permeability.
Changes in the gut microbiota can have a potent impact on the concentration of
metabolites and the infiltration of immune cells into the TME. Of particular interest, the
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Bacteroidetes phylum produces a variety of short chain fatty acids (SCFAs) including
acetic acid, propionic acid, succinic acid, and small amounts of butyric acid (Ormerod,
Wood, Lachner, Gellatly, Daly, Parsons, Dal'Molin, et al.; den Besten et al.; Louis and
Flint; Adamberg et al.; Finegold et al.; Ren et al.). In addition, members of the Firmicutes
phylum produce butyric acid and small amounts of propionic acid (Donohoe et al. "A
Gnotobiotic Mouse Model Demonstrates That Dietary Fiber Protects against Colorectal
Tumorigenesis in a Microbiota- and Butyrate-Dependent Manner"; den Besten et al.;
Louis and Flint; Revuelta et al.). SCFAs have different functions in the gut including
energy sources for the gut microbiota and intestinal epithelial cells, inhibitors of histone
deacetylases (HDACs), ligands for G protein-coupled receptors (GPCRs), and the
activation and expansion of immune cells (Rooks and Garrett). It is possible that loss of
the Bacteroidetes S24-7 population or expansion of the Firmicutes families may promote
changes in the metabolite concentrations in the gut. These may further have an impact on
the recruitment of immune cells into the TME. The results from these studies suggest that
assessing the changes in metabolite concentrations and the TME composition are critical
to understanding the mechanisms by which folate can impact the response of 5-FU on
CRC development.
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Figure 4.1: Alpha and Beta Diversity. Alpha diversity by (A)
observed OTUs (Operational Taxonomic units) and (B) rarefaction plot
of WT mice fed the RC diet and ApcMin/+ mice fed the RC, FF, and
FF+FA diets. Beta diversity (C) unweighted and (D) weighted
principal component plots of WT mice fed the RC diet and ApcMin/+
mice fed the RC, FF, and FF+FA diets. (* p< 0.05, ** p< 0.01, ns not
significant).
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Figure 4.2: Alterations in the Bacterial Phylum and Family in Response
to Diet. A. Phylum compositional changes in WT mice fed the RC diet and
ApcMin/+ mice fed the RC, FF, and FF+FA diets. B. The ratio of
Bacteroidetes to Firmicutes in WT and ApcMin/+ mice fed the RC, FF, and
FF+FA diets. C. Changes in microbial family composition in WT mice fed
the RC diet and ApcMin/+ mice fed the RC, FF, and FF+FA diets.
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Figure 4.3: Most Altered Microbes in the Gut in Response to Dietary
Changes. Changes in the abundance of (A) S24-7, (B) Coriobactericeae, (C)
Lactobacillus, (D) Ruminococcus sp., and (E) Clostridiales in ApcMin/+ mice fed
the RC, FF, and FF+FA diets. (* p< 0.05, ** p< 0.01, *** p< 0.001, **** p<
0.0001, ns not significant).
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CHAPTER 5
A FOLATE DEFICIENCY PROMOTES CHANGES IN GUT METABOLITE
CONCENTRATIONS
5.1 INTRODUCTION
Alterations to the gut microbiota can yield significant changes in the
concentration of metabolites present in the gut (den Besten et al.; Louis, Hold and Flint;
Tremaroli and Bäckhed). These include short chain fatty acids (SCFAs) which constitute
a large group of volatile metabolites produced in the gut through fermentation of
carbohydrates by anaerobic bacteria (den Besten et al.). SCFAs can function as inhibitors
of histone deacetylase (HDAC), an enzyme that can regulate gene expression but is also
known to drive the expansion and activation of hematopoietic and non-hematopoietic
cells. This inhibitory action of SCFAs regulates immune homeostasis and promotes the
establishment of a tolerant anti-inflammatory cell phenotype (den Besten et al.; Donohoe
et al. "A Gnotobiotic Mouse Model Demonstrates That Dietary Fiber Protects against
Colorectal Tumorigenesis in a Microbiota- and Butyrate–Dependent Manner"; Louis,
Hold and Flint; Ríos-Covián et al.; Rooks and Garrett; Vinolo et al.). In addition, studies
have shown that SCFAs can inactivate Nuclear Factor - κβ (NF-κβ) and TNF-α in
peripheral blood monocytes and neutrophils (Vinolo et al.). NF-κβ is a transcription
factor that stimulates cytokine production and cell survival, while TNF-α is a cytokine
that stimulates cell growth and differentiation (Usami et al.; Vinolo et al.). Specifically,
propionic and butyric acids have both been shown to upregulate FoxP3 expression and
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Treg cell differentiation to influence homeostasis and attenuation of colitis in mice
(Rooks and Garrett; Tao et al.). SCFAs have also been shown to function as ligands for
GPCRs (Sun et al.). GPCRs are expressed on the cell surface of a variety of cells
including colonic cells, colonic mast cells, neutrophils, eosinophils, and Treg cells,
peripheral mononuclear cells, apical membrane of colonic epithelium, macrophages,
monocytes, and dendritic cells (DCs) (Donohoe et al. "A Gnotobiotic Mouse Model
Demonstrates That Dietary Fiber Protects against Colorectal Tumorigenesis in a
Microbiota- and Butyrate-Dependent Manner"; W. Wu et al.; Ohira, Tsutsui and Fujioka;
Sun et al.). In addition to the diverse expression of these GPCRs, their physiological
functions range from mediating increased energy expenditure, hematopoiesis of DCs
from bone marrow, expansion of t-regulatory cells and macrophages, protection from
irritable bowel disease (IBD) and colitis, and promoting IgA response (Ohira, Tsutsui and
Fujioka; W. Wu et al.; den Besten et al.). Together these data show the powerful impact
of SCFAs and their anti-inflammatory effects in the gut microenvironment. Although
numerous lines of evidence suggest that SCFAs are beneficial to human health and
disease, their role in CRC has not been fully established. However, it is known that
immune-tolerance and immune-suppression by Treg cells is detrimental in CRC because
Treg cells inhibit the cytotoxic function of CD8+ T cells and prevent tumor cell death
(Antony et al.). Perhaps SCFAs produced by the gut microbiota may influence
homeostasis and increase the activation and infiltration of Treg cells during
tumorigenesis. However, under circumstances of tumorigenesis, inflammatory responses
that activate cytotoxic CD8+ T cells are preferred to effectively target and destroy the
tumor. It may be possible to alter the concentrations of SCFAs in the gut to influence the
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activation and infiltration of immune cells that will promote tumor cell death (Louis,
Hold and Flint). To further increase the complexity, the diverse ecosystem of gut
microbes and metabolites makes understanding the direct effect of one specific
metabolite in a system, where multiple shifts are occurring, challenging.
The goal in chapter five is to determine how SCFA concentrations in the gut are
altered as a consequence of CRC, diet modifications, and 5-FU treatment. Identifying
which SCFAs are altered may provide insight into how a FF diet in combination with 5FU promotes tumor suppression and 5-FU cytotoxicity. Folic acid is a co-factor that is
required for the formation of acetic, propionic, and butyric acids which are the most
abundant SCFAs present in the gut (Louis and Flint). Thus it is possible that SCFAs may
be altered in response to folate deficiency.
To determine the changes in SCFA levels, the cecum of WT and ApcMin/+mice
was analyzed. For each mouse strain, the following six groups (diet and treatment) were
processed: Rodent Chow + PBS, Rodent Chow + 5-FU, Folate Free + PBS, Folate Free +
5-FU, Folate Replete + PBS, and Folate Replete + 5-FU. The following six SCFAs were
analyzed: acetic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid, and
valeric acid. 2-ethyl butyric acid was used as the internal control. Approximately 50 mg
of cecal content was weighed and processed as described in chapter 8. SCFAs were
extracted into methyl tert-butyl ether (MTBE) and analyzed using gas chromatography –
flame ionization detection (GC-FID). Peaks were detected and the area under the curve
measured to determine the concentration of each SCFA that was present in each sample.
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5.2 RESULTS
Analysis from GC-FID indicated significant changes in the concentrations of the
different metabolites in response to CRC, dietary manipulation, and 5-FU. However, the
data showed the largest changes in SCFAs when mice were switched from the RC diet to
the defined FF and FF+FA diets. Although the results suggested that folate was not the
primary driver for changes in the SCFA concentrations, the data typically showed a
partially restored phenotype when folate was added back into the FF diet. This implied
that there are changes in SCFA concentrations that might have occurred in response to
folate levels and changing into the defined diets. It is unclear whether the composition of
SCFAs was impacted by the defined diets or the presence of 1% SST. In addition, it is
important to mention that WT mice showed consistent changes in SCFA levels in
response to diet and 5-FU whereas ApcMin/+ mice showed fluctuations that may be in part
due to the tumor burden in ApcMin/+mice. In this section, the changes in SCFA levels will
be described in both WT and ApcMin/+ mice that have been subjected to dietary
manipulations and 5-FU.

ACETIC ACID
Acetic acid, or ethanoic acid, is a two carbon SCFA that is highly abundant in
mice (Ríos-Covián et al.). Although the role of acetic acid has not been fully established,
it is known that acetic acid functions to inhibit enteropathogens, or disease causing
bacteria in the gut. The data showed that the concentrations of acetic acid were
significantly altered during CRC, dietary manipulation, and treatment 5-FU. WT mice fed
the RC diet reported elevated levels of acetic acid. Treatment with 5-FU caused a
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significant reduction in acetic acid concentrations (RC PBS 3.33 ± 1.12 versus RC 5-FU
1.57 ± 0.58, p=0.02). When WT mice were switch to FF or FF+FA diets, acetic acid
levels decreased significantly as compared to mice fed the RC diet (FF PBS 0.331 ± 0.24,
p=0.004; FF+FA PBS 1.55 ± 0.7, p=0.019). When subjected to 5-FU, acetic acid levels
remained low and were statistically similar as compared to untreated WT mice fed the FF
and FF+FA diets (FF 5-FU 0.43 ± 0.40, p= 0.58; FF+FA 5-FU 1.15 ± 1.05, p=0.49 ).
Furthermore, the acetic acid level observed in WT mice fed the FF were partially restored
to that in mice fed the RC diet when folic acid was added back into the diet.
ApcMin/+mice, on the other hand, had low levels of acetic acid when fed the RC, FF, and
FF+FA diets as compared to WT mice fed the RC diet (RC PBS 1.41 ± 0.73; FF PBS
0.39 ± 0.75; FF+FA PBS 0.71 ± 0.46). There was no statistical difference between mice
fed the RC diet and mice fed the FF (p= 0.09) or FF+FA (p=0.12) diets. When treated
with 5-FU, ApcMin/+mice fed the RC diet had increased levels of acetic acid as compared
to untreated control mice (RC 5-FU 4.352 ± 1.35, p=0.0052) whereas ApcMin/+mice fed
the FF and FF+FA diets remained at reduced levels (FF 5-FU 0.48 ± 0.23; FF+FA 5-FU
0.56 ± 0.42). There was no statistical difference between untreated mice fed the FF or
FF+FA diet as compared to 5-FU treated mice fed the FF (p=0.87) and the FF+FA
(p=0.73) diets.
Although the concentration of acetic acid remained low in mice fed the FF and
FF+FA diets during treatment with PBS or 5-FU, it is interesting to note that the presence
of tumors in ApcMin/+ mice modified the levels of acetic acid present in the gut. WT mice
fed the RC diet had higher levels of acetic acid whereas ApcMin/+mice fed the RC diet did
not. However, while acetic acid levels decreased during treatment of WT mice with 5-
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FU, in ApcMin/+ mice these levels increased. These results suggest that 5-FU in a WT
mouse may initiate inflammation and that 5-FU in a diseased mouse may alleviate
inflammatory conditions. ApcMin/+ mice exhibited decreased levels of this antiinflammatory SCFA regardless of diet. Perhaps treatment with 5-FU during CRC helps to
reduce inflammation and tumor progression. Our data showed that administering a FF or
FF+FA diet reduced levels of acetic acid in both WT and ApcMin/+ mice, and restored
levels when FA was added back into the diet in WT mice. Although it is difficult to
determine fully, it appears that folic acid in the diet stimulated the production of acetic
acid. In addition, the defined diets or 1% SST alone may suppress the gut microbes that
are responsible for acetic acid formation. Further studies are necessary to delineate the
impact of the defined diets and the presence of 1% SST.

PROPIONIC AND BUTYRIC ACID
Propionic acid, or ethanecarboxylic acid, is a three carbon SCFA and butyric acid,
or propanecarboxylic acid is a four carbon SCFA (Ríos-Covián et al.). Propionic and
butyric acid together with acetic acid are the SCFAs that have been studied immensely.
Propionic acid is only mildly abundant in the gut of mice whereas butyric acid is highly
abundant. Propionic and butyric acid have many similarities and overlap in function.
Butyrate and propionate are known to induce the differentiation of Treg cells and regulate
intestinal inflammation through the inhibition of HDACs. HDAC is an enzyme that
facilitates winding of DNA around histones to inactivate gene expression (Tao et al.).
Butyrate and propionate have numerous other functions that make these SCFAs
important aspects in obesity, colitis, and CRC (Louis, Hold and Flint).
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CRC, dietary manipulation, and treatment with 5-FU have significant effects on
propionic and butyric acid concentration in the cecum. WT mice fed the RC diet had
elevated levels of both SCFAs that are significantly reduced when subjected to 5-FU
(Propionic Acid: RC PBS 0.68 ± 0.15 versus RC 5-FU 0.43 ± 0.14; p=0.027) (Butyric
Acid: RC PBS 2.053 ± 0.49 versus RC 5-FU 1.32 ± 0.57; p=0.004). WT mice fed the FF
and FF+FA diets had reduced levels of propionic and butyric acid as compared to WT
mice fed the RC diet (Propionic Acid: FF PBS 0.041 ± 0.03, p=0.0008; FF+FA PBS 0.16
± 0.038, p=0.0018) (Butyric Acid: FF PBS 0.61 ± 0.21, p=0.0001; FF+FA PBS 0.90 ±
0.32, p=0.0001). These levels remained low during treatment with 5-FU (Propionic Acid:
FF 5-FU 0.05 ± 0.02; FF+FA 5-FU 0.04 ± 0.03) (Butyric Acid: FF 5-FU .78 ± 0.26;
FF+FA 5-FU 0.70 ± 0.40). However, there was a significant difference in propionic acid
levels between WT mice fed the FF+FA diet treated with PBS and 5-FU (P = 0.0019).
Similar to acetic acid, the elevated levels of propionic and butyric acid, observed in WT
mice fed the RC diet, were partially restored when folic acid was added back into the
diet. This suggested that folic acid in the diet may contribute to the production of these
SCFAs. In contrast, ApcMin/+mice fed the RC diet had lower levels of propionic and
butyric acid that were elevated during treatment with 5-FU (Propionic Acid: RC PBS
0.40 ± 0.22 versus RC 5-FU 0.65 ± 0.12; p=0.06) (Butyric Acid: RC PBS 1.14 ± 0.55
versus RC 5-FU 2.92 ± 1.12; p=0.0004). Similar to the WT mice, ApcMin/+mice fed the FF
and FF+FA diets had reduced levels of these SCFAs as compared to ApcMin/+ mice fed
the RC diet (Propionic Acid: FF PBS 0.04 ± 0.04, p=0.022; FF+FA PBS 0.10 ± 0.04,
p=0.037) (Butyric Acid: FF PBS 0.55 ± 0.52, p=0.17; FF+FA PBS 0.48 ± 0.24, p=0.16).
These levels remained low during treatment with 5-FU (Propionic Acid: FF 5-FU 0.09 ±
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0.069; FF+FA 5-FU 0.04 ± 0.03) (Butyric Acid: FF 5-FU 0.59 ± 0.28; FF+FA 5-FU 0.51
± 0.21). However, there was a significant reduction in propionic and butyric acid levels
between 5-FU treated ApcMin/+ mice fed the RC diet and 5-FU treated ApcMin/+ mice fed
the FF (Propionic Acid: p=0.0001; Butyric Acid: p=0.0001) or the FF+FA (Propionic
Acid: p=0.0004; Butyric Acid: p=0.0001) diets. Propionic acid levels were slightly
elevated in ApcMin/+mice fed the FF+FA diet suggesting partial restoration of SCFA
levels, although there was still a significant difference between ApcMin/+ mice fed the RC
and FF+FA diets (p=0.0004). Perhaps these changes have implications on the TME that
impact tumor regression and rejection in response to therapy.
Similar to the data with acetic acid, CRC modified the concentration of propionic
and butyric acid when mice are fed the RC diet. However, the FF and FF+FA diets
suppressed the levels of propionic and butyric acid which may be due to the defined diets,
folate deficiency, or inhibitor of folate production, 1% SST. In addition, the restoration
of the SCFAs upon addition of FA to the FF diet was only observed with propionic acid
but not butyric acid. The restoration was clearly observed in WT mice, but not the
ApcMin/+mice which may be due to their exacerbated diseased state as a factor
contributing to their unique response. Examining the modifications in SCFAs in WT
mice helped to establish the base line effects of diet on SCFA levels in the cecum.

5.3 SUMMARY AND DISCUSSION
This data showed specific changes in the composition of SCFAs that were a direct
result of CRC, dietary alterations, and 5-FU treatment. Most of the SCFA levels that were
lower in the presence of a FF diet were partially restored when FA was added back into
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the diet (FF+FA) indicating that FA in the diet has an impact on SCFA production in gut
metabolism and CRC disease progression. Acetic, propionic, and butyric acids are the
most abundant SCFAs present in the gut and are of particular interest because they all
play a role in immune activation and differentiation. We postulate that SCFAs may play a
role in modulating the TME as they are localized in the tumor and therefore can have
direct implications on the recruitment of immune cells into the TME. Future studies
where ApcMin/+mice are supplemented with individual SCFAs may indicate which SCFAs
are contributing to TME composition and tumor cytotoxicity in response to 5-FU.
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Figure 5.1: Short Chain Fatty Acid Composition. Changes in the
abundance of (A) acetic, (B) propionic, and (C) butyric acid in WT and
ApcMin/+ mice fed the RC, FF, and FF+FA diets that were treated with PBS
blue) and 5-FU (red). (* p< 0.05, ** p< 0.01, *** p< 0.001).
.
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CHAPTER 6
A FOLATE DEFICIENCY PROMOTES CHANGES IN THE TUMOR
MICROENVIRONMENT
6.1 INTRODUCTION
Previous chapters have shown that a FF diet in combination with 5-FU enhanced
the efficacy of anti-tumor therapy using 5-FU. Mice receiving this combination therapy
showed a lower tumor burden and systemic improvement based on spleen and mouse
weight, as well as hematopoietic parameters. These results may be a consequence of the
FF diet modifying the gut microbiota, causing a depletion of the Bacteroidetes S24-7
population and an expansion of the Firmicutes Ruminococcus and Clostridiales
populations. These alterations may in turn affect the concentration of SCFAs in the gut.
In particular, our data showed a significant reduction in acetic, propionic, and butyric
acids when mice were fed the FF and FF+FA diets with partial restoration in the FF+FA
diet when folate was added back. However, the diets were both folate deficient and also
inhibited folate production by the gut microbiota. Thus it is important to delineate these
two components to determine their impact on tumor response to therapy. It is known that
these SCFAs have potent implications of the activation and recruitment of immune cells
into the TME. Based on what is known, we hypothesize that a FF diet and 5-FU together
promote tumor cytotoxicity through manipulating the TME. To further determine the
mechanism underlying the enhanced 5-FU, we will characterize the immune cells
infiltrating the TME. Studies have shown that the TME plays a key role in the treatment
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of cancers (Peddareddigari, Wang and DuBois; Trédan et al.; Quail and Joyce; M.-L.
Chen et al.; Miselis et al.; Lin, Li, et al.; Lin, Nguyen, et al.; O'Callaghan et al.;
Zeisberger et al.; Gounaris et al.; Maltby, Khazaie and McNagny; Kitadai et al.;
Crawford et al.; Francia, Emmenegger and Kerbel; Ryan et al.; Yasuhiko et al.). For
example, there is evidence showing that host-tumor interactions can facilitate protumorigenic and anti-tumorigenic immune responses. We hypothesize that innate immune
cells like myeloid-derived suppressor cells (MDSCs), mast cells, and macrophages
infiltrate the tumor to create an inflammatory environment that promotes tumorigenesis.
In addition, we hypothesize that adaptive immune cells, such as Treg cells and cytotoxic
T cells, have opposing effects on CRC development. Treg cells, which function to
regulate and control inflammatory responses, are thought to have a negative impact on
tumor regression by suppressing the immune responses to tumorigenesis. On the other
hand, cytotoxic T cells are thought to promote tumor regression by destroying cancer
cells. It is unknown how 5-FU administered with a FF diet can modulate the TME.
Determining which immune cells are infiltrate the TME may help to elucidate their
function and provide insight into the mechanism underlying the enhanced cytotoxicity of
5-FU.
In addition to assessing the infiltration of these cells into the TME, it is also
important to determine their circulating levels to assess the systemic effects of dietary
manipulation and 5-FU treatment. As previously discussed, the effects of a FF diet and 5FU therapy are systemic and local to the TME. Our data showed that the combination
therapy has systemic effects as determined by an increase in mouse body weight,
decrease in spleen weight, and improvement of hematopoietic parameters. However, our
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data also showed that the combination therapy also exerts its effects locally through
alterations in the gut microbiome composition that may lead to changes in SCFA
concentrations, and a decrease in tumor burden. Incorporating the circulating levels of
immune cells into the analysis will provide evidence of the systemic effects of combined
therapy that will supplement the local TME analysis.
Therefore, the goal in chapter six is to determine how the TME and systemic
microenvironment are affected by a FF diet and 5-FU. Identifying which immune cell
populations are present, absent, or modified may provide insight as to how the TME
facilitates tumor cytotoxicity of ApcMin/+ mice.
To study the changes in the TME, six experimental groups were analyzed (diet
and treatment): Rodent Chow + PBS, Rodent Chow + 5-FU, Folate Free + PBS, Folate
Free + 5-FU, Folate Replete + PBS, and Folate Replete + 5-FU. Three mice from each
group were selected and three tumors were imaged per mouse tissue to yield a total of
nine tumors per group. Tissues were embedded in 13% acrylamide and cut 200 µm thick
using a tissue vibratome. Tissues were stained with conjugated antibodies against cell
surface markers for mast cells (CD117+ and FcEr1a+), macrophages (F4/80+),
granulocytes (Gr1+), T-regulatory cells (Treg cells) (CD4+ and FoxP3+), and cytotoxic T
cells (CD8+). Stained tissue sections were imaged using the Zeiss LSM 510 META
Confocal Scanning Laser Microscope at the University of South Carolina, School of
Medicine. Images were taken at 20x magnification and the entire region of each tumor
was imaged. Immune cells were counted to determine the total number of a particular
immune cell present within the tumor.
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To assess changes in circulating levels of immune cells, peripheral blood was
collected from the retroorbital sinus of mice at four time points: prior to 5-FU
administration, after administration of the first round of 5-FU, after one week of rest in
between 5-FU administration, and at sacrifice. The same experimental groups used above
were analyzed. To establish the baseline circulating immune cell levels, peripheral blood
obtained prior to 5-FU administration was collected after the mice had been transferred to
their new diets for three weeks prior to receiving any chemotherapy. 75 µL of blood was
processed for flow cytometry to detect mast cells, macrophages, and MDSCs. Data
collected from flow cytometry represents the percentage of each particular immune cell
present in a given sample.

RESULTS
6.2A: A FOLATE DEFICIENT DIET AND 5-FU MODULATE THE TUMOR
MICROENVIRONMENT
Analysis of the tumor sections indicated that several changes in the cellular
composition of the TME occurred as a result of dietary manipulation and 5-FU treatment.
The data showed that the greatest changes occurred when mice were transferred from the
RC to the defined FF and FF+FA diets. In this section, we assessed the number of
immune cells including mast cells, macrophages, granulocytes, Treg cells and cytotoxic T
cells in tissues from mice receiving different diets and/or 5-FU therapy. The number of
cells was normalized against the tumor size. We found that normalizing had no
significant effect on the amount of immune cell infiltration, suggesting that the size of the
tumor did not impact the abundance of these immune cells in the TME.
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MAST CELLS
Mast cells are members of the innate immune system and play a major role in
protection against pathogens and parasites (Marshall). Mast cells can secrete
inflammatory mediators, attract other inflammatory immune cell populations, and
promote tissue repair; however, the behavior of the mast cell depends heavily on the
extrinsic signal received (Maciel, Moura and Hermine). Mast cells also play a role in
angiogenesis, immune tolerance, defense against pathogens, and wound healing (AponteLópez et al.; Maciel, Moura and Hermine). Mast cells have had a controversial role in
tumor development and progression. Conflicting data have implicated that mast cell
accumulation in tumors as either beneficial or harmful to tumor development and
progression (Aponte-López et al.; Maciel, Moura and Hermine). Other data have shown
conflicting correlations with metastasis, patient survival, and prognosis (Aponte-López et
al.; Maciel, Moura and Hermine). However, a larger amount of data implicates mast cells
as being pro-tumorigenic because they are capable of initiating angiogenesis and tissue
remodeling (Aponte-López et al.; Maciel, Moura and Hermine).
ApcMin/+mice fed the FF and FF+FA diets had similar levels of mast cell
infiltration which was significantly lower as compared to mice fed the RC diet (RC PBS
17.42 ± 8.649; FF PBS 9.70 ± 8.11, p=0.044; FF+FA PBS 9.10 ± 9.398, p=0.046).
Adding back FA did not significantly alter the levels of mast cells in mice fed the FF+FA
diet as compared to mice fed the FF diet (p=0.88) (Figure 6.1A). Thus, infiltrating mast
cells are not impacted by folate levels in the diet. When subjected to 5-FU, mice fed the
RC diet showed a significant reduction in infiltrating mast cells that were similar to the
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level of mast cells infiltrates in mice fed FF diet treated with PBS or 5-FU (RC 5-FU 7.70
± 6.13, p=0.0062). Interestingly, when FA was restored to the FF+FA diet, there was an
increase in the infiltration of mast cells into the TME when mice were treated with 5-FU
(FF+FA 5-FU 14.29 ± 4.92). This data suggests that the FF+FA diet combined with 5-FU
creates an inflammatory TME through the enhanced recruitment of mast cells. This data
suggests that mast cells may be a key immune cell that is responsible for altering the
TME and facilitating a pro-tumorigenic microenvironment when folate is present.
However, mice fed the RC and FF+FA diets had different levels of mast cell infiltration,
suggesting that FA alone was not the sole mechanism of this enhanced inflammation.

MACROPHAGES
Macrophages are members of the innate immune response and play a major role
in phagocytosis, non-specific defense mechanisms, and activation of adaptive-specific
defense (Martinez and Gordon). Specifically, macrophages are essential for T cell
activation. They are classified into pro-inflammatory M1and anti-inflammatory M2
macrophages (Martinez and Gordon). In addition, tumor associated macrophages (TAMs)
belong to both M1 and M2 subtypes and have been shown to be involved in cancerpromoting inflammation and suppression of T-cell anti-tumor immunity (Ostuni et al.).
Although macrophages have a dual function, they are commonly perceived as
contributors to tumor development and therefore are associated with poor prognosis
across a variety of cancers (L., J. and E.; J. J. W. Chen et al.; DeNardo et al.; Di Caro et
al.; Steidl et al.).
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Macrophages were significantly reduced in ApcMin/+ mice fed the FF and FF+FA
diets as compared to their levels in mice fed the RC diet (RC PBS 49.50 ± 28.35; FF PBS
5.818 ± 4.47, p=0.0001; FF+FA PBS 9.85 ± 11.17, p=0.0002). However, there was no
significant difference in macrophage infiltration between mice fed the FF and FF+FA
diets suggesting that macrophages are not impacted by FA levels (p=0.17) (Figure 6.1B).
When subject to 5-FU, mice fed the RC diet had a significant reduction in macrophages
as compared to the PBS treated controls (RC 5-FU 27.36 ± 14.78, p=0.0204).
Macrophage infiltration was also slightly elevated in mice fed the FF and FF+FA diets
that were treated with 5-FU as compared to the PBS treated controls; however, these
were not statistically significant (FF 5-FU 16.88 ± 13.72, p=0.059; FF+FA 5-FU 18.45 ±
11.17, p=0.054). In addition, there was no statistical difference in macrophage infiltration
between mice fed the RC, FF, or FF+FA diets that were treated with 5-FU although there
was a slight reduction in mice fed the FF and FF+FA diets. Although we are able to
determine the general pattern and changes in immune infiltration, further characterization
of the macrophages, as M1 and M2 macrophages, will be needed to determine if their
function as pro-inflammatory or anti-inflammatory.

MDSCs
MDSCs are a heterogeneous population of immunosuppressive myeloid cells that
inhibit T cell differentiation (De Sanctis et al.). Expansion of MDSCs occurs during
chronic inflammatory conditions such as cancer and leads to angiogenesis and tumor
progression (De Sanctis et al.). Cancer patients with a high infiltration of MDSCs in the
TME typically have poor prognosis (Gabrilovich and Nagaraj). Because of their negative
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impact on immune-stimulation, MDSCs have become a critical focus in cancer research.
MDSCs are typically characterized by the cell surface marker CD11B+ and Gr1+;
however, in this study we will use the Gr1+ marker to assess the MDSC population.
The results from this study showed that granulocytes are significantly reduced in
the TME of mice fed the FF and FF+FA diets as compared to mice fed the RC diet (RC
PBS 32.00 ± 18.57; FF PBS 3.89 ± 3.90, p=0.0003; FF+FA PBS 7.67 ± 4.98, p=0.0009).
Although granulocytes were slightly higher in mice fed the FF+FA diet as compared to
mice fed the FF diet, the data was not statistically significant (p=0.069) (Figure 6.C).
When subjected to 5-FU, mice fed the RC diet showed a slight increase in granulocyte
infiltration as compared to the PBS treated controls; however, this was not statistically
significant (RC 5-FU 37.30 ± 25.10; p=0.59) . Mice fed the FF and FF+FA diets that
were treated with 5-FU showed enhanced infiltration of granulocytes as compared to the
PBS treated controls, but this did not reach the levels detected in mice fed the RC diet
(FF 5-FU 12.82 ± 9.86, p=0.017; FF+FA 5-FU 19.50 ± 9.09, p=0.0084). MDSCs are
typically considered as negative prognostic markers in CRC, therefore, a reduction in
MDSCs in mice fed the FF and FF+FA diets may help to reduce tumor development and
improve response to therapy. In addition, a reduction in MDSCs in the TME may slow
tumor growth and recurrence.

T-REGULATORY CELLS
CD4+ T cells are categorized into T helper (Th) cells and T-regulatory (Treg)
cells. Treg cells are members of the adaptive immune system and have been shown to
play a major role in tolerance and suppression of the immune system, particularly tumor-
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specific CD8 T cells (M.-L. Chen et al.; Corthay; Mougiakakos et al.; Takeuchi and
Nishikawa). In addition, Treg cells are important for autoimmunity and protection from
commensal bacteria (Corthay; Mougiakakos et al.; Takeuchi and Nishikawa). The role of
Treg cells in cancer has become complicated due to their functional diversity (Corthay;
M.-L. Chen et al.; Curiel; Mougiakakos et al.; Takeuchi and Nishikawa). Treg cells are
elevated in patients with cancer and hinder the effects of therapy and thus, correlate with
poor patient survival (Curiel; Mougiakakos et al.; Takeuchi and Nishikawa). In support of
this notion, Treg cells play a role in immunoediting where they stimulate immune
tolerance to cancer cells. Evidence shows that a high ratio of Teff/Treg cells in the tumor
promotes tumor rejection (Quezada et al.). Controlling the amount of infiltrating Treg
cells may improve patient prognosis. Due to the complexity and significance of Treg cells
in cancer, we determined if folate plays a role in Treg cell accumulation in the TME.
The results from our studies showed that immune infiltration of Treg cells was
significantly reduced in mice fed the FF and FF+FA diets as compared to mice fed the
RC diet (RC PBS 48.67 ± 18.16; FF PBS 14.56 ± 8.06, p= 0.0001; FF+FA PBS 21.27 ±
23.78, p=0.0064). In addition, there was no significant difference in Treg cell infiltration
between mice fed the FF and FF+FA diets (p=0.40) (Figure 6.1D). When subjected to 5FU, mice fed the RC diet had a significant reduction in Treg cell infiltration into the TME
as compared to untreated controls whereas mice fed the FF and FF+FA diets showed no
significant change (RC 5-FU 18.00 ± 7.86, p=0.0001; FF 5-FU 9.143 ± 7.86, p=0.20;
FF+FA 5-FU 20.50 ± 9.12, p=0.92). Because Treg cells are known to induce immune
tolerance, the elimination of Treg cells in the tumor bed may provide a beneficial
advantage to mice fed the FF and FF+FA diets. Consistent with these results, upon
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treatment with 5-FU Treg cells remained at low levels in mice fed the FF and FF+FA
diets as compared to mice fed the RC diet where Tregs were significantly reduced.
Overall, the results indicate that both the FF and FF+FA diets facilitate an antitumorigenic TME before treatment with 5-FU. Furthermore, a FF diet further suppresses
Treg infiltration when mice are treated with 5-FU suggesting that the combined effect of
no dietary folate and inhibition of folate producing bacteria is the most beneficial to the
mice.

CYTOTOXIC T CELLS
Cytotoxic T cells are members of the adaptive immune response and play a major
role in destruction of damaged, infected, and cancerous cells (Gajewski, Schreiber and
Fu; Bennett et al.). T-cells are activated by innate antigen presenting cells and CD4 Th
cells to facilitate T-cell specific killing. Cytotoxic T cells are essential to anti-tumor
immunity and elevated levels of cytotoxic T cells promote tumor regression and patient
survival (Naito et al.; Phan et al.; Tosolini et al.). High infiltration of cytotoxic T cells
would therefore aid in destroying the tumor. Because of the beneficial properties for
cytotoxic T cells, we determined their abundance in the TME of the mice in the
experimental groups.
The results from this study showed that cytotoxic T cells are significantly reduced
in the TME of mice fed the FF and FF+FA diets as compared to mice fed the RC diet
(RC PBS 25.09 ± 16.14; FF PBS 4.00 ± 5.37, p=0.0017; FF+FA PBS 4.00 ± 6.28,
p=0.0018). However, there was no significant difference in cytotoxic T cell infiltration in
the TME between mice fed the FF and FF+FA diets (p=1.00). When subjected to 5-FU,
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mice fed the RC diet had a significant reduction in cytotoxic T cell infiltration into the
TME as compared to untreated controls whereas mice fed the FF and FF+FA diets
showed no significant changes (RC 5-FU 0.77 ± 1.17, p=0.0006; FF 5-FU 1.00 ± 0.82,
p=0.052; FF+FA 5-FU 3.80 ± 4.96, p=0.94).
These results suggest that the defined diets or SST may be contributing to
alterations in the recruitment of cytotoxic T cells into the TME. However, since
cytotoxic T cells are beneficial in suppressing tumor development, perhaps cytotoxic T
cells may not be responsible for the enhanced cytotoxicity of 5-FU in mice fed the FF
diet. Furthermore, cytotoxic T cells were significantly reduced upon treatment with 5-FU,
This is consistent with the previous data in the literature where repeated treatments of 5FU caused a depletion and impairment of cytotoxic T cell function (Y. Wu et al.).

6.2B: A FOLATE DEFICIENT DIET AND 5-FU MODULATE CIRCULATING
LEVELS OF IMMUNE CELLS
Analysis by flow cytometry showed that circulating levels of immune cells were
altered during treatment with 5-FU rather than diet modifications. In this section, we
assessed the numbers of circulating mast cells, macrophages, and MDSCs in WT and
ApcMin/+mice that were fed the different diets and were treated or not with 5-FU.

MAST CELLS
As described above, mast cells are innate immune responders that play a major
role in angiogenesis, immune tolerance, and protection (Aponte-López et al.; Maciel,
Moura and Hermine). WT mice fed the RC, FF, and FF+FA diets had low levels of
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circulating mast cells; while the mice fed the FF and FF+FA diets showed a gradual
increase in mast cells over time. This did not rise to the level of significance. When
subjected to 5-FU, WT mice fed the FF diet showed an increase in circulating levels of
mast cells whereas mice fed the RC and FF+FA diets did not. These elevated levels were
reduced by the time of sacrifice. Overall, the largest change in mast cell infiltration was
observed in WT mice fed the RC diet and treated with 5-FU (WT: RC PBS 0.63 ± 0.10
versus RC 5-FU 1.60 ± 0.42, p=0.02) (Figure6.2A-D).
ApcMin/+mice on the RC diet had relatively similar levels of circulating mast cells
as compared to the WT mice, that increased steadily throughout their lifetime.
ApcMin/+mice fed the FF and FF+FA diets had reduced levels of mast cells after treatment
with PBS. Following PBS treatment, mast cell levels in mice fed the FF diet increased
while those in mice fed the FF+FA diet fluctuated until the time of sacrifice. When
subjected to 5-FU, there was no significant change in mast cell levels in mice fed the RC
diet. However, in mice fed the FF and FF+FA diets, mast cell levels were immediately
reduced after 5-FU treatment, followed by a significant increase after the rest week. Mast
cell levels remained high in mice fed the FF diet similar to the PBS treated controls at the
time of sacrifice and partially normalized in mice fed the FF+FA diet similar to the PBS
treated controls by the time of sacrifice. Overall, there were no significant changes in the
circulating levels of mast cells in ApcMin/+mice at sacrifice (Figure 6.2E-H).
This data shows that mice fed the FF diet have elevated circulating levels of mast
cells upon treatment with 5-FU and that these levels remain elevated until the time of
sacrifice. These data suggest that mast cell differentiation and production is affected by 5-
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FU in the ApcMin/+mice and perhaps a FF diet may contribute to the enhanced activation
of mast cells.

MACROPHAGES
Macrophages are innate immune responders that play a major role in T cell
activation as well as phagocytosis and non-specific host defense (Ostuni et al.; Martinez
and Gordon). The circulating levels of mast cells in WT mice fed the RC, FF, and FF+FA
diets remained at steady levels throughout their lifetime. When subjected to 5-FU,
macrophages in WT mice fed the RC diet were rapidly diminished; however, they
returned to pre-treatment levels during the rest week. On the other hand, circulating
levels of macrophages in WT mice fed the FF diet were quickly diminished following
treatment with 5-FU, but recovered to pretreatment levels. Similarly, circulating levels of
mast cells in WT mice on the FF+FA diet were reduced by 5-FU treatment, and partially
recovered to the pre-treatment levels after the rest week. Overall, circulating macrophage
levels in mice fed the FF and FF+FA diets that were treated with 5-FU were lower
relative to the mice that were fed the RC diet. Although 5-FU caused a reduction in
circulating mast cell levels in all mice on the different diets, the largest reduction was
observed in WT mice on the FF+FA diet (WT: FF+FA PBS 7.125 ± 0.85 versus FF+FA
5-FU 1.20 ± 0.28, p=0.0009 ) (Figure6.3 A-D).
Macrophage levels n ApcMin/+mice fed the RC and FF+FA diets showed a
continued decrease over the experimental period while levels stayed constant in
ApcMin/+mice on the FF diet. Treatment with 5-FU reduced the circulating macrophage
levels in mice fed the RC, FF, and FF+FA diets. Macrophage levels remained relatively
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low when ApcMin/+mice are fed the RC and particularly the FF diets and treated with 5FU as compared to ApcMin/+mice fed the FF+FA diet, whose levels increased after the rest
week. Overall, macrophage levels are most reduced in ApcMin/+mice fed the FF diet and
treated with 5-FU (Figure 6.3 E-H).
These data showed that in mice fed the FF diet, circulating levels of macrophages
are significantly diminished and remain at low levels upon treatment with 5-FU. Their
loss may play an important role in tumor rebound after 5-FU treatment.

MDSCs
MDSCs are a heterogeneous population of immunosuppressive myeloid cells that
inhibit T cell differentiation. WT mice fed the RC, FF, and FF+FA diets had low levels
of circulating MDSCs. Treatment with 5-FU caused a significant reduction in circulating
MDSCs that recovers after a rest week (Figure 6.4 A-C). Because MDSCs only expand
during inflammation, WT mice had similar levels of circulating MDSCs regardless of
diet that significantly decreased during treatment with 5-FU. The most significant
changes in circulating MDSC levels was in response to treatment with 5-FU across all
three diets wherein there was a significant reduction in their levels (Figure 6.4A-D).
ApcMin/+ mice on the RC diet had fluctuating levels of circulating MDSCs.
reported elevated levels of MDSCs that became reduced during treatments with PBS. At
the time of sacrifice, ApcMin/+mice fed the RC diet had elevated levels of circulating
MDSCs as compared to ApcMin/+mice fed the FF and FF+FA diets, who had reduced
levels of circulating MDSCs. Upon treatment with 5-FU, circulating levels of MDSCs in
ApcMin/+mice fed the RC, FF, and FF+FA diets were significantly reduced, however, they
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recovered to near pre-treatment levels during the rest week. Overall, ApcMin/+ mice fed the
RC, FF, and FF+FA diet show decreased levels of circulating MDSCs as compared to
PBS treated controls; however ApcMin/+ mice fed the FF diet showed the most significant
reduction in MDSCs after treatment with 5-FU as compared to PBS treated controls (FF
PBS 25.70 ± 2.26 versus FF 5-FU 9.30 ± 2.24, p=0.0001) (Figure 6.4E-H).
Collectively, these data showed that treatment with 5-FU causes a significant
reduction in circulating MDSC levels that was further enhanced when ApcMin/+mice are
fed the FF diet, where their levels remained low. This potentially contributes to the
enhanced response and tumor cytotoxicity observed in these mice. Elimination of folate
in the diet may minimize the recovery of MDSCs and may help to keep the immune
system in check, preventing tumor growth.

6.3 SUMMARY AND DISCUSSION
Together, these results indicate that the TME is significantly altered when mice
are fed the FF and FF+FA diets. Mice fed the RC diet showed an abundant infiltration of
the TME by all of the immune cells examined. When these mice were subjected to 5-FU,
the infiltration of mast cells, macrophages, Treg cells, and cytotoxic T cells was
significantly reduced. However, in mice fed the FF and FF+FA diets, there was a
significant reduction in the infiltration of the TME by all the immune cell populations
including, mast cells, macrophages, granulocytes, Treg cells, and cytotoxic T cells as
compared to mice fed the RC diet. In addition, treatment with 5-FU in mice fed the FF
and FF+FA diets did not affect the infiltration of these immune cell populations. These
data suggest that diminishing the number of immune cells that are infiltrating the TME
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may create an anti-tumorigenic TME that causes the tumors to be more susceptible to 5FU therapy in mice fed the FF and FF+FA diets.
Although these results did not show that the diet impacts the circulating levels of
mast cells, macrophages, or MDSCs, these results did show that circulating levels these
immune cell populations were impacted by CRC and 5-FU. In addition, treatment of
ApcMin/+ mice with 5-FU caused a reduction of mast cells, macrophages, and MDSCs;
however, ApcMin/+ mice fed the FF diet had the most significant reduction in MDSCs.
Because MDSCs can be detrimental to tumor progression and recurrence.it is important
to manage the circulating levels of these immune cells. The reduction in circulating
MDSCs in mice fed the FF diet also correlated with the reduction of MDSCs in the TME
suggesting that the FF diet may help prevent the activation and expansion of MDSCs into
the TME. Removing MDSCs, an immune cell population that plays a significant role in
cytotoxic T cell suppression, may enhance the cytotoxicity of 5-FU. In addition, Treg
cells were also significantly reduced in the TME when ApcMin/+ mice were fed the FF diet
and these levels remained reduced during treatment with 5-FU. Blocking the infiltration
of an immunosuppressive cell that promotes immune regulation and tolerance like Treg
cells is essential to enhance tumor regression through cytotoxic T cells. These data
suggest that the FF diet in combination with 5-FU therapy shifts the tumor-immune
response from pro-tumorigenic to anti-tumorigenic.
When examining the circulating levels before and after treatment, after rest, and at
the time of sacrifice, ApcMin/+ mice fed the FF+FA diet that were treated with 5-FU
showed the largest fluctuations in mast cells, macrophages, and MDSCs as compared to
ApcMin/+ mice fed the RC or FF diets that were treated with 5-FU. These results suggest
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that the FF+FA diet may enhance inflammation and cause adverse effects systemically.
These results are consistent with the increased anemia observed in ApcMin/+ mice fed the
FF+FA diets that had an enlarged spleen and required three rounds of 5-FU therapy to
achieve healthy levels of HCT, HGB, and RBCs. ApcMin/+ mice fed the FF diet on the
other hand only required one round of 5-FU therapy to achieve healthy levels of HCT,
HGB, and RBCs.
Although this data showed how CRC, dietary modifications, and treatment with
5-FU altered the circulating levels and recruitment of immune cells into the TME, it is
essential to determine the molecular mechanisms that are influencing these changes.
Because our results suggest that MDSCs and Treg cells are playing a major role in tumor
response to 5-FU therapy, future studies will determine how a FF diet prevents the
infiltration of these populations into the TME. Our results suggest that the gut
microbiome is responsible for these changes; therefore, repeating these studies using a
GF mouse model will help establish how specific microbes are influencing the activation
and infiltration of these immune cell populations.
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Figure 6.1: Recruitment of Bone Marrow Derived Cells into the Tumor
Microenvironment. The total counts of (A) mast cells, (B) macrophages,
(C) granulocytes, (D) t-regulatory cells, and (E) cytotoxic T cells into the
TME of ApcMin/+ mice fed the RC, FF, and FF+FA diets that were treated
with PBS (blue) or 5-FU (red). (* p< 0.05, ** p< 0.01, *** p< 0.001, ns not
significant).
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Figure 6.2: Circulating Levels of Mast Cells. The circulating levels of mast
cells before initial treatment with 5-FU, after treatment with 5-FU, after the
rest week, and at sacrifice in WT mice fed the (A) RC, (B) FF, and (C) FF+FA
diets and in ApcMin/+ mice fed the (E) RC, (F) FF, and (G) FF+FA diets. Blue
represents PBS treated mice and red represents 5-FU treated mice. Bar graphs
represent the total percentage of mast cells at sacrifice in (D) WT and (H)
ApcMin/+ mice fed the RC, FF, and FF+FA diets. (* p< 0.05).
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Figure 6.3: Circulating Levels of Macrophages. The circulating levels of
macrophages before initial treatment with 5-FU, after treatment with 5-FU,
after the rest week, and at sacrifice in WT mice fed the (A) RC, (B) FF, and (C)
FF+FA diets and in ApcMin/+ mice fed the (E) RC, (F) FF, and (G) FF+FA diets.
Blue represents PBS treated mice and red represents 5-FU treated mice. Bar
graphs represent the total percentage of mast cells at sacrifice in (D) WT and
(H) ApcMin/+ mice fed the RC, FF, and FF+FA diets. (* p< 0.05, ** p< 0.01,
*** p< 0.001).
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Figure 6.4: Circulating Levels of Myeloid Derived Suppressor Cells (MDSC)
The circulating levels of MDSCs before initial treatment with 5-FU, after
treatment with 5-FU, after the rest week, and at sacrifice in WT mice fed the (A)
RC, (B) FF, and (C) FF+FA diets and in ApcMin/+ mice fed the (E) RC, (F) FF, and
(G) FF+FA diets. Blue represents PBS treated mice and red represents 5-FU
treated mice. Bar graphs represent the total percentage of mast cells at sacrifice in
(D) WT and (H) ApcMin/+ mice fed the RC, FF, and FF+FA diets. (* p< 0.05, **
p< 0.01, *** p< 0.001).
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CHAPTER 7
THE ROLE OF SUCCINYL SULFATHIAZOLE
7.1 INTRODUCTION
In the previous sections, the FF and FF+FA diets contained 1% SST, an antibiotic
the inhibited the production of folate by gut bacteria. The FF diet had complete
elimination of FA by both the diet and 1% SST whereas the FF+FA diet contained FA,
but had 1% SST. Therefore, two major questions arise: what are the effects driven by
folate deficiency in the diets, and what effects are driven by inhibition of folate
production by the antibiotic, 1% SST. To delineate these effects, we performed the
experiments using a folate deficient diet that lacks SST.
Thus, the goal in this chapter is to examine the effect of dietary folate deficiency
on tumor burden, hematopoietic toxicity, gut microbiome composition, SCFA
concentrations, and the immune cell infiltration into the TME without inhibiting gut
folate production.
We used the same experimental designed that was previously described.
ApcMin/+mice were fed the RC diet up to 10 weeks of age and then randomly assigned to
either a basal or FF* (folate deficient diet without SST) diets. The basal and FF* diets are
folate replete and folate defined diets respectively that do not contain SST. Similar
analyses were completed to assess tumor burden, hematopoietic toxicity, changes in the
gut microbiota, SCFA concentration, and TME composition.
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RESULTS:
7.2A: ABSENCE OF SUCCINYL SULFATHIAZOLE REVERSES TUMOR
REGRESSION AND PROTECTION FROM HEMAOPOIETIC TOXICITY WHEN
TREATED WITH 5-FU
The results from these studies showed that removal of the antibiotic SST reversed
the enhanced cytotoxicity of 5-FU therapy. The removal of SST had no significant effect
on mouse and spleen weight (Figure 7.1A-B). ApcMin/+mice fed the basal and FF* diets
had similar tumor burden (p=0.75) that remained similar when treated with 5-FU
(p=0.69). Mice fed the basal diet that were treated with 5-FU had a 17% reduction in total
tumor burden as compared to PBS treated controls (Basal PBS 50.79 ± 16.78 versus
Basal 5-FU 42.31 ± 24.03; p=0.430). Mice fed the FF* diet that were treated with 5-FU
had a 30% reduction in total tumor burden as compared to PBS treated controls (FF* PBS
53.88 ± 20.19 versus FF* 5-FU 38.25 ± 13.16, p=0.095) (Figure 7.1 D). These results
were also consistent for tumors that were >1mm (Figure 7.1 E). However, when ApcMin/+
mice were fed the FF diet that contains 1% SST, tumor burden decreased 70% during
treatment with 5-FU as compared to PBS treated controls. In addition, removal of SST
caused a loss of hematopoietic protection as HCT, HGB, and RBC levels were
significantly lower than the healthy range during treatment with 5-FU. Our data showed
that mice fed the FF* diet were able to regain healthy measures of the hematopoietic
parameters after three rounds of 5-FU; in contrast, mice fed the basal diet showed a
continued decline in these parameters. These data suggest that elimination of dietary
folate combined with inhibition of folate production by gut bacteria may protect the mice
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from hematopoietic toxicity. Restoration of folate production by the gut microbiota was
sufficient to increase hematopoietic toxicity of 5-FU (Figure 7.1C).

7.2B: ABSENCE OF SUCCINYL SULFATHIAZOLE NORMALIZED THE GUT
MICROBIOTA
The results from 16S ribosomal sequencing of genomic DNA from fecal pellets
revealed an increase in species richness when ApcMin/+ mice were fed the FF* diet as
compared to mice fed the basal diet (Figure 7.2A). In addition, there were differences in
species diversity in mice fed the basal as compared to those on the FF diets as seen in
weighted PCoA plot, which takes into account the relative abundance of each taxa within
the communities (Figure 7.2B). This clear separation disappeared in the unweighted
PCoA plot suggesting that the effects were driven by the relative abundance of specific
taxa rather than the species present within the communities amongst the different cohorts
(Figure 7.2C). Analysis of the gross composition shifts at the phylum level revealed that
Bacteroidetes were the most abundant phylum present followed by the Firmicutes
(Figure 7.2D). At the family level, the S24-7 family of the Bacteroidetes was the most
abundant family present in the samples (Figure 7.2E). These data strongly indicate that
inhibition of folate production by the gut microbiota rather than dietary folate deficiency
was critical for enhancing tumor response to therapy, potentially by specifically
eliminating the Bacteroidetes S24-7 population. Similar to previous results, the
Firmicutes Ruminococcus and Clostridiales remained abundant suggesting that these
microbes were not altered by the diet or SST (Figure 7.2E).
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7.2C: BASAL AND FF* DIETS MODIFY THE SCFA CONCENTRATIONS AND
TME COMPOSITION
The results from GC-FID analysis SCFAs from the cecal content indicated that
the diets contributed to the reduction of SCFA concentrations in the cecum. Acetic,
propionic, and butyric acids all remained low when mice were fed the basal and FF* diets
and were similar to levels seen in the previous experiment (Figure 7.1 A-C). When mice
were fed the basal and FF* diets, propionic acid levels increased slightly and butyric acid
levels decreased slightly. However, none of these changes were statistically significant
(Figure 7.3 A-C).
Examination of the TME revealed a significant reduction of all immune cell types
into the TME including mast cells, macrophages, MDSCs, and t-regulatory cells.
Cytotoxic T cells were the only cell type that were elevated when ApcMin/+ mice were fed
the basal and FF diets as compared to the previous study. Perhaps the presence of the
antibiotic SST present in the other diets promoted the infiltration of immune cells into the
TME, such that when mice fed the FF diet with SST were treated with 5-FU, it was more
cytotoxic to the tumors and caused their regression. It is possible that some of the
immune cells such as MDSCs and macrophages created a TME wherein 5-FU was more
cytotoxic to the tumor. Previous studies have shown that 5-FU is selectively cytotoxic to
MDSCs and may recruit CD8+ T cells that secrete IFN-γ that aid in killing tumor cells
(Apetoh et al.).
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7.3 SUMMARY AND DISCUSSION
In this chapter, we delineated the impact of the dietary folate deficiency and
inhibition of folate production by the gut microbiota, SST, on tumor response to therapy,
hematopoietic toxicity, metabolite concentration in the gut, and the TME composition.
These data indicate that inhibition of FA produced by gut microbes is essential to reduce
tumor burden in ApcMin/+mice in response to 5-FU. The data further suggests that folate
from the gut microbiota can confer resistance to 5-FU by modifying the TME and
metabolite concentrations in the gut.
In addition, SST also alters the gut microbiota composition by specifically
eliminating the Bacteroidetes S24-7 population. Removing the antibiotic restored this
population and altered tumor response to 5-FU therapy. Future studies need to examine
the newly discovered bacterial population and the mechanisms by which it can confer
resistance to 5-FU therapy.
The composition of SCFAs remains depleted in ApcMin/+mice fed the basal and
FF* diets suggesting that the defined diets reduced the concentrations of SCFAs. This
refutes our hypothesis that the changes in the gut microbiota would alter the composition
of SCFAs. In addition, the basal and FF* diets significantly reduced the infiltration of
mast cells, macrophages, MDSCS, and Treg cells into the TME as compared to
ApcMin/+mice fed the RC diet. In addition, the recruitment of mast cells and Treg cells
into the TME were significantly reduced in mice fed the basal or FF* diets that were
treated with PBS or 5-FU as compared to mice fed the FF+FA or FF diets containing 1%
SST that were treated with PBS or 5-FU (data not shown). The recruitment of
macrophages and MDSCs into the TME were also significantly reduced in mice fed the
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basal or FF* diets as compared to the mice fed the FF+FA and FF diets, with the
exception of mice fed the FF* and FF diets that were treated with PBS (Macrophages
P=.14; MDSCs P=.14). These results showed that the folate deficiency reduced the
infiltration of macrophages and MDSCs, regardless of the presence of SST. Finally, there
was no significant difference in the infiltration of CD8+ T cells between mice fed the
basal and FF* diets that were treated with PBS or 5-FU as compared to mice fed the
FF+FA and FF diets, with the exception of mice fed the FF* and FF diets that were
treated with 5-FU (p=0.034). Overall, the infiltration of these immune cells increased
when ApcMin/+mice were fed the FF and FF+FA diets that contain SST suggesting that the
antibiotic is responsible for the enhanced infiltration of immune cells into the TME. Yet,
the infiltration of these immune cells into the TME remains significantly reduced in mice
fed the basal. FF*, FF, and FF+FA diets compared to mice fed the RC diet. It is possible
that the absence or presence of these immune cells is functioning to create an antitumorigenic TME to promote tumor regression and rejection. Future studies will
determine how these immune cells are functioning in the tumor stroma to promote to
suppress tumor development.
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Figure 7.1: Loss of Succinyl Sulfathiazole on Mouse and Spleen Weight,
Hematopoietic Parameters, and Tumor Burden. Changes in (A) mouse
weight and (B) spleen weight in ApcMin/+ mice fed the RC, basal, and FF diets
and treated with PBS (blue) or 5-FU (red). C. The hematopoietic parameters of
Min/+
Apc
mice fed the basal and FF diets. Solid lines represent mice fed the
basal diet and dashed lines represent mice fed the FF diet. The yellow bar is
indicative of the healthy range for each hematopoietic parameter. D. Total
tumor burden and tumors >1mm in ApcMin/+ mice fed the basal and FF diets
and treated with PBS or 5-FU. E. Total tumor burden of ApcMin/+ mice fed the
RC and basal diets and treated with PBS (blue) or 5-FU (red). (* p< 0.05, **
p< 0.01, ns not significant).
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Figure 7.2: Loss of Succinyl Sulfathiazole on the Gut Microbiota. Alpha
diversity by rarefaction plot of ApcMin/+ mice fed the basal and FF diets. Beta
diversity (B) weighted and (C) unweighted principal component plots of ApcMin/+
mice fed the basal and FF diets. (D) Phylum and (E) family gross compositional
shifts amongst ApcMin/+ mice fed the basal and FF diets.
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Figure 7.3: SCFA levels and Immune Cells in the TME in Mice fed the Basal
and FF* Diets. Changes in the abundance of (A) acetic acid, (B) propionic acid,
Min/+
and (C) butyric acid in Apc
mice fed the basal and FF diets and treated with
PBS (blue) or 5-FU (red). Changes in the abundance of (D) mast cells, (E)
macrophages, (F) granulocytes, (G) t-regulatory cells, and (H) cytotoxic T cells
Min/+
in APC
mice fed the basal and FF diets and treated with PBS (blue) or 5-FU
(red). (* p< 0.05, ** p< 0.01, *** p< 0.001, ns not significant).
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CHAPTER 8
PROPOSED MECHANISM OF A FOLATE DEFICIENCY AND CHEMOTHERAPY
ON TUMOR RESPONSE
8.1 INTRODUCTION
The results from these studies provide the mechanism for which a FF diet
contributes to enhanced cytotoxicity of 5-FU. ApcMin/+mice fed the FF diet had a
significant reduction in spleen weight as compared to ApcMin/+ mice fed the RC and
FF+FA diets that remained low during treatment with 5-FU. The body weight increased
significantly as well when ApcMin/+ mice fed the FF diet were treated with 5-FU therapy.
These mice had the highest body weight at the time of sacrifice as compared to ApcMin/+
mice fed the RC and FF+FA diets. In addition, ApcMin/+ mice fed the FF diet recovered
healthy levels of HCT, HGB, and RBCs after one round of 5-FU therapy. The presence of
FA in the FF+FA diet reversed these beneficial effects. ApcMin/+mice fed the FF+FA diet
had a reduced spleen weight that significantly increased upon treatment with 5-FU to
levels observed in ApcMin/+ mice fed the RC diet. These mice also required three rounds
to 5-FU therapy to recover healthy levels of HCT, HGB, and RBCs.
ApcMin/+mice fed either the RC, FF, or FF+FA diets had no significant difference
in tumor burden suggesting that dietary manipulation alone was not sufficient to reduce
tumor development. However, upon systemic treatment with 5-FU, ApcMin/+mice fed the
FF diet had at significant 70% reduction in tumor burden surpassing ApcMin/+ mice fed the
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RC and FF+FA diets. It is evident that removal of dietary folate and folate production by
gut microbes enhances the cytotoxic effects of 5-FU.
Analysis from 16S ribosomal sequencing of fecal pellets showed that
ApcMin/+mice on the FF and FF+FA diets had a significant reduction in the Bacteroidetes
S24-7 family and an expansion of the Firmicutes Ruminococcus and Clostridiales
families as compared to mice fed the RC diet. These gross compositional changes are a
direct result of the presence of SST in the diet, as removal of SST in the basal and FF*
diets reversed these effects. In addition, mice fed the FF and FF+FA diets had a
significant reduction in acetic, propionic, and butyric acids as compared to mice fed the
RC diet. The Bacteroidetes phylum is major producers of propionic and acetic acids
whereas the Firmicutes phylum is major producers of butyric acid respectively. Despite
the fact that the levels of butyric acid decreased, the Firmicutes phylum expanded.
However, acetic acid is used as a CoA-transferase for the conversion of butyryl-CoA to
butyrate (Louis and Flint). It is likely that the reduction in acetic acid is removing the cofactor required to form butyrate and decreasing the concentration of butyrate in the
cecum.
These changes in the gut microbiota and SCFA composition reduced the
recruitment of immune cells into the TME. Mice fed the FF and FF+FA diets had a
significant reduction in mast cells, macrophages, granulocytes, Treg cells, and cytotoxic
T cells as compared to mice fed the RC diet. These data also correlated with the reduction
of circulating MDSCs and macrophages suggesting that a FF diet enhances anti-tumor
immunity.
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Upon removing SST using the basal and FF* diets, it is evidence that altering the
gut microbiota is essential to enhance the cytotoxic effects of 5-FU. The gut microbiota
composition of mice fed the basal and FF* diets was normalized, such that the
Bacteroidetes S24-7 was abundant. The distribution of Bacteroidetes S24-7 and the
Firmicutes Ruminococcus and Costridiales shared similar abundance to WT and ApcMin/+
mice fed the RC diet. However, the SCFA concentrations remained consistent to levels
present in mice fed the FF and FF+FA diets suggesting that the changes in the gut
microbiota by SST are not altering the composition of SCFAs. In mice fed the basal and
FF* diets, the recruitment of immune cells into the TME was reduced as compared to
mice fed the FF+FA and FF diets that contain 1% SST. Understanding how the specific
abundance of these immune cells in the TME enhances the cytotoxicity of 5-FU still
needs to be established.
These results suggest that the defined diets are responsible for reducing the
composition of SCFAs and the recruitment of immune cells into the TME, whereas the
antibiotic is responsible for targeting and manipulating the gut microbiota. If we do not
alter the gut microbiota, 5-FU is unable to effectively kill the tumors. In conclusion,
administering a folate deficient diet that contains SST to inhibit the production of folate
by gut microbes is essential to alter the gut microbiota to maximize the cytotoxicity of 5FU therapy. Our results confirm that it is essential block dietary folate and folate
produced by the gut microbiota to enhance the cytotoxic effects of 5-FU therapy. The
schematic diagram provides our proposed mechanism (Figure 8.1).
Future studies will determine the impact of SST in mice fed a RC diet. Using the
same experimental design, mice will receive either RC or RC + 1% SST diets to
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determine if altering the gut microbiota is sufficient to enhance the cytotoxic effects of 5FU. If mice can be administered a regular chow diet that contains an antibiotic to alter the
gut microbiota, then perhaps altering the gut microbiota of patients in the clinical setting
would enhance the cytotoxic effects of 5-FU, without requiring drastic changes to their
diet. Nonetheless, it is essential to determine whether folate needs to be eliminated from
the diet, the gut microbiome, or both. In addition, future studies will examine the activity
of immune cells in the TME. Using the same experimental design, mice will be
euthanized after one and three rounds of 5-FU therapy to determine how 5-FU influences
the activation and infiltration of immune cell populations and how this contributes to
enhanced cytotoxicity of 5-FU. In addition, characterizing the immune cell populations,
to delineate pro-inflammatory M1 or anti-inflammatory M2 macrophages among others,
will be essential to determine the inflammatory state in mice fed the FF diet.
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Figure 8.1: Schematic Diagram. This study showed that ApcMin/+ mice fed a
folate deficient diet with 1% SST had a significant reduction of the Bacteroidetes
S24-7 and an expansion of the Firmicutes Ruminococcus and Clostridiales.
Subsequently, the composition of SCFAs, specifically propionic, acetic, and
butyric acid were significantly reduced. Our data suggests that altering the gut
microbiota through a folate deficient diet significantly reduced the recruitment of
mast cells, macrophages, MDSCs, Treg cells, and cytotoxic T cells. This altered
gut microbiota and TME creates an anti-tumorigenic microenvironment to
enhance the cytotoxicity of 5-FU therapy to promote tumor regression and
rejection, and improve survival.
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CHAPTER 9
MATERIALS AND METHODS
Mouse Strains
C57Bl/6 and ApcMin/+mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). Animal procedures were performed according to the guidelines and
approval of the University of South Carolina Institutional Animal Care and Use
Committee.

Diets
Rodent chow 5001 (RC) (LabDiet, St. Louis MO) was used as our regular diet
control. Folate free 58C3 (FF) and folate free + 6ppm (parts per million) folic acid 57KH
(FF+FA) diets were synthesized (TestDiet, St. Louis, MO). Both diets are identical with
the exception that the FF+FA diet contains 6ppm of folic acid. Both diets contain 1%
succinylsulfathiazole, an antibiotic that reduces folate production and interferes with
folate absorption and metabolism. This experimental design allows us to distinguish the
impact of folate consumed in the diet and the impact of folate producing bacteria. Basal
and FF diets were synthesized (TestDiet, St. Louis, MO). These diets are identical except
the basal contains 6ppm folic acid and the FF contains no folic acid. Neither of these
diets contains SST.
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Serum Isolation
Blood was collected in Heparin-coated capillary tubes and stored in EDTA coated
vials (Thermofisher, Pittsburg, PA; Becton Dickinson, Franklin Lakes, NJ) through the
retro-orbital vein. Blood samples were analyzed using the VetScan HM5 Hematology
Analyzer (Abaxis, Union City, CA). Samples were centrifuged at 10,000 g for five
minutes to pellet the RBCs. The supernatant containing serum was stored in
microcentrifuge tubes at -80°C until further analysis.

Pellet Collection
Animals were placed in individually clean cages without bedding. Pellets were
collected from the bottom of the cage using sterilized tweezers and placed into clean
1.5mL Eppendorf tubes. Tubes would be frozen immediately in dry ice and later stored at
-80°C.

5-FU Dosing
5-FU was prepared at 4mg/mL in 1x PBS and filter sterilized using a .2µm filter.
Mice were weighed prior to each dosing and administered 40mg/kg of 5-FU. Mice
received an intraperitoneal injection if 5-FU using a 21G syringe.

Sacrifice
Mice were euthanized by cervical dislocation and tissues were immediately
harvested. The spleen and liver were excised, weighed, and cut into two fragments. One
fragment was flash frozen in dry ice and ethanol and the other fragment was placed in 4%
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paraformaldehyde (PFA). The cecum was excised and flash frozen in dry ice and ethanol.
The small intestines of ApcMin/+mice were cut into four equal parts. The small intestines
and colon were flushed with PBS and cut down the middle to lay the intestines flat on
whatman filter paper. Four intestine segments and one colon segment were stored in 4%
PFA overnight and moved to 1% PFA the next day.

Tumor Counting
Intestines were harvested from the animals, cut open and positioned flat on filter
paper. Intestines were cut into four segments for the small intestine plus one segment for
the colon. Tumors were counted using .1% methylene blue stain. Tumors were counted
from each segment of the intestines for total tumor count and tumors >1mm.

Stool Isolation
DNA was isolated from pellets using the QIAamp DNA Stool Mini Kit (Qiagen).
Pellets were isolated following their procedure provided on their website. Pellets were
homogenized in ASL buffer. The supernatant was collected and resuspended with an
InhibitEX Tablet. The solution was centrifuged and the supernatant was collected, and
mixed with AL buffer and proteinase K. The solution was incubated at 70⁰ C for 10
minutes. Ethanol was added to the mixture and centrifuged through the QIAamp spin
column. Spin column was washed once with AW1 buffer and twice with AW2 buffer.
DNA was eluted in AE buffer and stored at -20⁰ C until further dilution for 16S
ribosomal sequencing.
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16S Ribosomal Sequencing
DNA isolated from pellets underwent 16S ribosomal metagenomics sequencing
using the NextSeq500 Next Generation Sequencing instrument (Illumina, San Diego,
CA). V3 and V4 regions were PCR amplified using gene-specific primers. Amplified
regions were purified using beads to remove the primers from the amplicon. This PCR
clean up step occurs twice. Libraries were quantified using dsDNA fluorometric
quantification binding dyes. Libraries were denatured for cluster generation and
sequencing. Control and amplicon libraries were loaded into MidSeq to classify the reads
at each taxonomic level. R1 and R2 FASTQ files were generated and analyzed using
QIIME data software.

Gas Chromatography – Flame Ionization Detector
The gas chromatography – flame ionization detector (GC-FID) technique was
used on mouse cecal content to study short chain fatty acids (SCFAs). The SCFAs of
interest are acetic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid, and
valeric acid (Sigma, St. Louis, MO). 2-ethyl butyric acid (Sigma, St. Louis, MO) was
used as an internal control. Approximately 50 mg of cecal content was weighed,
recorded, and placed into a microcentrifuge tube. One milliliter of 0.5% phosphoric acid
solution diluted in water was added to the cecal content. In addition, five microliters of
10mM 2-ethyl butyric acid solution diluted in water was added. One mm zirconium oxide
beads (NextAdvance, Troy, NY) were added to the microcentrifuge tube to homogenize
the cecal content. Samples were centrifuged at 13,000 RPM for 10 minutes and the
supernatant was removed and placed into a fresh microcentrifuge tube. 400uL of methyl
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tert-butyl ether (MTBE) was added to the tube and the sample was vortexed for 30
seconds. Samples were centrifuged again at 13,000 RPM for 10 minutes. The supernatant
was removed and placed in a polytetrafluoroethylene (PTFE) cap-sealed two milliliter
glass vial (VWR, West Chester, PA) to be processed.
Standard curve was generated by determining the amount of each SCFA present
in 50 mg of cecal content. For each SCFA, seven standards were made to cover the
micromolar (µM) range of SCFA abundance: acetic acid (150-12,000 µM), propionic
acid (25-2,000 µM), isobutyric acid (5-1,000 µM), butyric acid (5-1,000 µM), isovaleric
acid (5-1,000 µM), and valeric acid (1-1,000 µM). Standard curve was used to determine
the exact amount of each SCFA present in each sample in micrograms per microliter
(µg/µL).

Tissue Processing
Three ApcMin/+mice were selected for tissue processing from the following six
treatment groups: RC+ PBS, RC + 5-FU, FF + PBS, FF + 5-FU, FF+FA + PBS, FF+FA
+ 5-FU. Mouse tissues that were selected had a tumor burden nearest the mean tumor
burden within the treatment group. From each intestine, a total of three tumors were
processed and imaged yielding a total of nine tumors per treatment group.
Intestines were fixed in 4% PFA in PBS at pH 7.2. One tumor and surrounding
healthy intestines was excised and embedded in 13% acrylamide + ammonium persulfate.
Embedded tissues were stored at 4⁰ C for 45 minutes. Tissues were then cut at 200µm
thickness using the vibratome tissue slicer. Cut tissues were placed in 1% PFA in
phosphate buffered saline (PBS) until tissue staining.
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Tissue Staining
Tissues were stained for the presence of t-regulatory (treg) cells (CD4 and
FoxP3), mast cells (CD117 and FcεR1α+), cytotoxic T cells (CD8), macrophages (F4/80),
and granulocytes (Gr1). Samples were stained with primary antibodies: CD4 (goat pAb
sc-1140, Santa Cruz Biotechnology, Dallas, Texas), Foxp3 (rabbit pAb ab54501, Abcam,
Cambridge, United Kingdom), CD117 (rabbit pAb LS-191740, LifeSpan BioSciences,
Seattle, Washington), FcεR1α (goat pAb sc-33484, Santa Cruz Biotechnology, Dallas,
Texas), CD8 (rat mAb ab22378, Abcam, Cambridge, United Kingdom), F4/80 (rat mAb
ab16911, Abcam, Cambridge, United Kingdom), Gr1 (rat mAb 108401, Biolegend, San
Diego, California). Samples were stained with secondary antibodies: Cy-2 anti-goat 705225-147, Cy-3 anti-rabbit 711-165-152, and Cy-3 anti-rat 712-165-153 (Jackson
ImmunoResearch, West Grove, PA). Nuclei were stained with 4’, 6-diamidino-2phenylindole (DAPI) (Life Technologies, Eugene, OR) at a 1:5,000 dilution. Filamentous
actin (F-actin) was stained with phalloidin AF488 A12379 and AF633 A22284 (Life
Technologies, Eugene, OR).
Tissues were washed with PBS, 0.01 Glycine, 0.1% Triton-X three times for 30
minutes and blocked with 5% bovine serum albumin (BSA) in PBS and 5% Normal
Donkey Serum (NDS) (Jackson ImmunoResearch, West Grove, PA) in 1% BSA in PBS
for one hour. Primary antibody was applied at a 1:100 dilution and incubated at 37°C for
one hour. Tissues were washed in 1% BSA two times for 15 minutes and blocked in 5%
NDS in 1% BSA in PBS for one hour. Secondary antibody was applied at a 1:100
dilution and incubated at 37°C for one hour. Tissues were washed in 1% BSA two times
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for 15 minutes and once in PBS for 15 minutes. Phalloidin in PBS was applied at a 1:50
dilution and incubated at room temperature for two hours. Tissues were rinsed in PBS
three times for 15 minutes. DAPI was applied at a 1:5,000 dilution for 15 minutes.
Finally, tissues were rinsed in PBS for 15 minutes followed by mounting tissue sections
to slides.
Tissues were mounted onto microscope slides using 80µL of 1, 4-Diazabicyclo
(2.2.2) octane (DABCO). Fragments of cover glass were on the sides of the tissues
section to elevate the coverslip and prevent distorting the tissue. Edges of the coverslip
were sealed with a thin layer of clear nail polish. Slides were stored at 4°C.

Confocal Microscopy
Mounted tissue slides were imaged using the Zeiss LSM 510 META Confocal
Scanning Laser Microscope at 20x magnification. The entire region of the tumor was
imaged to detect the total number of an immune cell population in the tumor region.

Tumor Size Measures
Tumor sections were imaged at 4x magnification on the EVOS FL Auto cell
Imaging System (Invitrogen, Frederick, MD). Tiff files were uploaded to ImageJ
software (NIH, Bethesda, MA), and the region of interest function was utilized to
measure the size of the tumor region in pixels. Immune cell counts per tumor were
normalized to the size of the time in pixels.
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Flow Cytometry
70µL of blood was collected from mice and lysed in 1x RBC lysis buffer at room
temperature for 15 minutes. Samples were centrifuged at 2,500 rotations per minute
(RPM) for five minutes. Supernatant was removed and the pellet was resuspended in
1mL 1% BSA in PBS containing CD16/32 Fc blocker (101302, Biolegend, San Diego,
CA). Samples incubated with Fc blocker for 10 minutes to prevent false positive results
from antibodies binding to the Fc region of immune cells rather than the FaB region.
Samples were again centrifuged and resuspended in respective antibody cocktails. The
following conjugated monoclonal antibodies were used: CD117 (PE 105808), FcEr1a
(PE Cy-7 134318), CD11B (PE 101208), F4/80 (AF647 123122), Gr1 (eFluor450
108430) (Biolegend, San Diego, CA). Antibody cocktails were incubated with sample at
room temperature for 45 minutes. Solution was centrifuged and resuspended in 500uL of
1% BSA in PBS and immediately analyzed using the BD FACS ARIA cell sorter.

Statistical Analysis
Data was expressed as the mean +_ standard deviation (SD). Statistical analysis of
two value sets was compared using a two-tailed t-test with Welch’s correction using
GraphPad Prism version 5.00 for Windows, (GraphPad software, San Diego California
USA, www.graphpad.com). P-values of p< 0.05, p< 0.01, and p< 0.001, p< 0.0001 were
considered statistically significance and indicated in the figures by *, **, ***, ****
respectively.
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